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Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized 
by the progressive loss of upper and lower motor neurons. In contrast, Parkinson Disease 
(PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons 
within the substantia nigra region of the brain. Recently, a number of genes have been 
identified to be involved in the progression of these diseases, this study focuses upon four 
ALS-related genes: TARDBP(TBPH), p62/SQSTM1(Ref(2)P), TBK1(IK2), and 
VCP(TER94). These genes have been linked to the autophagy pathway and its sub-type, 
mitophagy, which have been suggested to play substantial roles in the progression of ALS 
and PD. Employing the Drosophila model organism, I have investigated the consequences 
of the altered expression of these ALS-related genes in combination with modified PD 
gene activities in an attempt to discover potential interactions and similarities between the 
biological basis of neurodegenerative diseases and aging. Notable observations show that 
the inhibition of TBPH in the motor neurons leads to a reduction in longevity and 
locomotor ability, and, in complementary experiments, inhibition of TBPH in the 
developing neuron-rich Drosophila eye reduces the ommatidia and interommatidial bristle 
counts. The overexpression of IK2 in the motor neurons reduces longevity and locomotor 
ability. The inhibition of Ref(2)P in the motor neurons, as well as in the dopaminergic 
neurons, increases median lifespan, slightly, while severely reducing locomotor ability, 
which may suggest a compensational relationship between longevity and motor function. 
The inhibition of Ref(2)P and parkin in the ddc-Gal4-expressing neurons provided an 
increase in lifespan, while resulting in a reduction in locomotor ability. Investigation of 
 ii 
the inhibition of TER94 provided variable results, however I have shown that inhibition of 
TER94 in the dopaminergic neurons can reduce longevity and locomotor ability over 
time. The co-inhibition of TER94 and parkin has shown a marked reduction in lifespan 
(by ~30%) and a reduction in locomotor ability. In contrast, the inhibition of TER94 in 
combination with the expression of alpha-synuclein has shown an large increase in 
lifespan (by ~28%), with an accompanying reduction in locomotor ability over time. 
Investigation of these candidate genes and their role in a model of human disease 
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Chapter 1 – Introduction And Overview 
 
1.1 Purpose 
The neurodegenerative diseases, Amyotrophic Lateral Sclerosis (ALS) and 
Parkinson Disease (PD), have a high prevalence in our society. Despite being very 
common, much has been left unclear with regards to the pathogenesis of the diseases. The 
research presented herein focuses on four ALS-related genes: TARDBP(TBPH), 
p62/SQSTM1(Ref(2)P), TBK1(IK2), and VCP(TER94). The aim of this study is that 
through the manipulation of the expression of a select group of ALS and PD genes, there 
is the great potential to create extremely versatile models of these diseases through 
Drosophila melanogaster. These models have the potential to develop a better 
understanding of how these genes influence the longevity and locomotor ability of the 
organism. Specifically, the relationship between mitochondrial function and the 
consequences that ALS and PD genes may have upon this organelle is of great emphasis 
in this study. 
 
1.2 Amyotrophic Lateral Sclerosis  
The neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) is one of the 
most common adult-onset motor neuron diseases. Characterized by the progressive loss of 
upper and lower motor neurons of the spinal cord, brain stem, and motor cortex, ALS 
progression eventually leads to muscle weakness and atrophy (Scotter, Chen, & Shaw, 
2015). To date, at least three major ALS-associated genes have been identified, along 
with several other, less prominent ALS-linked genes that have been associated with the 
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disease. The major genes include superoxide dismutase 1 (SOD1), Fused in Sarcoma 
(FUS) and TAR DNA Binding Protein (TARDBP), and the others include Sequestosome-1 
(p62/SQSTM1), Optineurin (OPTN), TANK-binding kinase 1 (TBK1), VAMP-associated 
protein B (VAPB), and Valosin Containing Protein (VCP) (Andersen & Al-Chalabi, 2011; 
Nguyen, Thombre, & Wang, 2018). For the most part, these genes are linked to the 
cellular process of autophagy and its mitochondrial-directed sub-type mitophagy, both of 
which have been suggested to play substantial roles in the progression of 
neurodegenerative diseases such as ALS. As age increases, the prevalence of ALS 
continues to grow, with a median age of onset of 55 years (Pasinelli & Brown, 2006), and 
patients are typically surviving for three to five years after diagnosis (Schmolck, Mosnik, 
& Schulz, 2007). In general it is believed widely that genetics can explain only a fraction 
of many ALS cases, as the majority seem to arise sporadically, to suggest that 
approximately 10% of cases to have a familial basis. Most research involving ALS 
pathogenesis has been centred around mutations in the SOD1 gene. However, the focus 
has recently shifted to other ALS-associated genes and their protein products, such as the 
DNA/RNA-binding protein TDP-43, encoded by the TARDBP gene, along with the recent 
discovery of TBK1 as an ALS gene (Lagier-Tourenne & Cleveland, 2009; Oakes, Davies, 
& Collins, 2017). There is currently no cure and few treatments for this motor neuron 
disease. Focusing research upon a number of ALS-linked genes opens the possibility of 
the development of treatments and therapies.  
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1.3 Parkinson Disease  
Parkinson Disease (PD) is a common neurogenerative disease with a prevalence 
of 4 to 5% of the population over the age of 85 (Trinh et al., 2014). Similar to ALS,  the 
majority of PD cases are considered to be sporadic, while the remaining ~10% seem to 
have a familial basis (Eriksen, Wszolek, & Petrucelli, 2005). The central pathology of PD 
involves cell loss within the substantia nigra, a basal structure located in the human 
midbrain. When compared to unaffected individuals, this brain region has been shown to 
have a 50 to 70% loss of neurons by the time of the individuals death (Cheng, Ulane, & 
Burke, 2011). The progression of this disease results in individuals that exhibit a resting 
tremor, muscular rigour, posture instability, and bradykinesia. The primary PD genes 
include alpha-synuclein (SCNA), parkin and PINK1, along with others such as leucine-
rich repeat kinase 2 (LRRK2) and Parkinsonism associated deglycase (PARK7). Similar 
to ALS, several PD genes, including parkin and PINK1, have vital roles in mitophagy. 
The alpha-synuclein protein is essential in PD, as it is highly expressed in the neurons and 
is involved in a range of neurodegenerative disorders, including Alzheimer disease, the 
accumulation of this protein is toxic to human neurons (Polymeropoulos et al., 1997). A 
well-known indicator of PD is the presence of alpha-synuclein-immunoreactive 
inclusions, also referred to as Lewy bodies, comprised of proteins that are responsible for 
proteolysis and the degradation of proteins. These inclusions are known to reside in 
various locations such as the substantia nigra, hypothalamus, cerebral cortex, locus 
ceruleus, nucleus basalis, cranial nerve motor nuclei and the central and peripheral 
divisions of the autonomic nervous system (Polymeropoulos et al., 1997). Mutations in 
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the alpha-synuclein gene, as well as mutations in parkin and PINK1, two proteins 
essential in mitophagy, are known to result in the progression of PD (Evans & Holzbaur, 
2018). As PD has no cure although some treatments exist that provide some temporary 
relief, the cellular and molecular pathways governing disease progression must be 
investigated further.  
 
1.4 Mitochondria and Neurodegenerative Disease 
Mitochondria are cytoplasmic organelles that are responsible for the maintenance 
of homeostasis, carrying out vital cellular functions such as ATP production, redox 
signalling and programmed cell death (Franz, Kevei, & Hoppe, 2015; Reddy, 2009). The 
quality and quantity of mitochondria are kept at equilibrium due to regulated biogenesis 
and the process of mitophagy, a form of selective autophagy responsible for the 
degradation of damaged and dysfunctional mitochondria (Franz et al., 2015; Oakes et al., 
2017). In particular, mitophagy is a vital process in neurons as these cells seem to be 
more vulnerable to mitochondrial dysfunction than other cell types (Rodolfo, Campello, 
& Cecconi, 2018). Evidence has shown that compromised mitophagy can be a strong 
factor in the progression of PD, as a functional decline in mitophagy within the 
dopaminergic neurons has been identified as a characteristic of PD (Bingol & Sheng, 
2016). The PD genes, PINK1 and parkin, encode protein components essential to 
regulation of mitophagy: PINK1-parkin-mediated mitophagy being a widely investigated 
mechanism. In this pathway, PINK1 and parkin, among others, act together to mark, 
degrade and clear damaged mitochondria (Ashrafi, Schlehe, LaVoie, & Schwarz, 2014; 
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Whitworth & Pallanck, 2017). Parkinson Disease has been reported to arise when 
mutations occur in the PINK1 and parkin genes to impair mitophagy (Heo, Ordureau, 
Paulo, Rinehart, & Harper, 2015). However, compromised mitophagy has been linked to 
cases of ALS as well as PD. A reduction in mitophagy function, specifically within the 
motor neurons, in combination with an increase in dysfunctional mitochondria has been 
linked to degeneration of ALS neuromuscular junctions (NMJs) and ALS neuropathy 
(Rogers et al., 2017). Processes such as mitophagy, are essential in the homeostasis of 
many cell types, without proper clearance of damaged organelles, the perfect scenario for 
rapid disease pathogenesis is created. The desire for a more complete understanding of 
the link between mitochondrial dysfunction and neurodegenerative disease provides a 
strong motive to conduct further research into this relationship.  
 
1.5 Mitochondria and Age 
Impairment, coupled with abnormalities of the mitochondria, represent a major 
factor in both aging and age-related diseases, particularly neurodegenerative diseases. 
However, causal factors for many age-related neurodegenerative diseases, such as PD and 
ALS, are unknown (Reddy, 2009). Many studies have been conducted to investigate the 
link between the nervous system, age, autophagy and mitophagy, but many unanswered 
questions still remain. Compromised autophagy in conjunction with an increasing age 
further contributes to disease (Martinez-lopez, Athonvarangkul, & Singh, 2015). 
Abnormal macroautophagic processes, such as mitophagy, has been reported to associate 
with age in many systems, such as Saccharomyces cerevisiae and Caenorhabditis elegans 
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(Hansen & Rubinsztein, 2018). Based upon such observations, many studies have linked 
macroautophagy to the quality control of the mitochondrial population and suggests that 
the mechanisms that contribute to the continuous loss of the responsible processes of 
control strongly influence the aging process. (Hansen & Rubinsztein, 2018; Martinez-
lopez et al., 2015). Advanced age is considered to be a significant risk factor in the 
development of neurodegenerative disease and is known to be an essential contributor in 
both genetic and sporadic forms of the disorders. The mechanisms that are behind the 
interaction between aging and genetic predispositions to contribute to neurodegeneration 
are still unclear (Xu et al., 2018). However, the aging process is linked to a reduction of 
the physiological functions within tissues. Therefore, understanding the roles that 
autophagy may play in specific tissue types, such as nervous system and muscle tissues, 
with an emphasis upon aging is extremely important (Hansen & Rubinsztein, 2018). As 
the nervous system and muscle are essential tissue types in neurodegenerative disease, the 
mechanisms responsible must be further investigated. 
 
1.6 Drosophila melanogaster as a Model Organism 
Drosophila melanogaster has been a standard model organism in many scientific 
laboratories throughout the world, in particular to those who study models of human 
diseases, for over a hundred years. The popularity of this model organism stems from the 
many advantages that the organism offers that other model organisms lack. These benefits 
include short lifespan, which allows for the quick production of data. A rapid generation 
time of ten to twelve days, to provide a large amount of offspring and allow experiments 
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to be conducted in a relatively short period; as well as they are inexpensive to maintain 
and require little resources (Jeibmann & Paulus, 2009). However, the most essential 
advantage that the Drosophila system offers may be the similarity to humans in regards to 
many biological, physiological and neurological properties. Using the fly as a model 
organism is particularly important in those interested in studying human disease, as 
according to genomic studies, approximately 75% of human disease-causing genes 
having a functional homologue in Drosophila melanogaster (Pandey & Nichols, 2011). 
By investigating the consequences of altered expression of such disease-causing genes in 
the fly, we may gain a better understanding of the mechanisms that contribute to disease 
progression.  
 
Many genetic techniques can be carried out in Drosophila that allows for gene 
manipulation and provides researchers with the ability to understand biological processes 
in non-human species. A commonly used method for tissue-specific expression of a gene 
in Drosophila is the transcription activation system known as the UAS/Gal4 system, a 
method of genetic manipulation in which gene expression can be studied in model 
organisms. The two key parts of this system are a transactivator gene, Gal4, and a effector 
gene, containing the upstream activation sequence (UAS). The Gal4 gene encodes the 
yeast transcription activator protein Gal4, while the UAS sequence is an enhancer which 
Gal4 binds to in order to activate the transcription of a gene. It is when the Gal4 portion 
binds to the UAS enhancer sequences located in the DNA that the transgene can be 
expressed in a time/tissue-dependent manner, allowing for the Drosophila homologue of 
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the gene to be inserted in various tissues of the fly, such as the motor neurons (Barwell et 
al., 2017; Jeibmann & Paulus, 2009). The UAS/Gal4 system is a critical molecular tool in 























Figure 1.1: Comparison of Homo sapiens TDP-43 protein (A) and Drosophila 
melanogaster TBPH protein (B) with conserved domains. Highlighted are the N-terminal 








Figure 1.2: Comparison of Homo sapiens TBK1 protein (A) and Drosophila 
melanogaster IK2 protein (B) with conserved domains. Highlighted are the P kinase 





Figure 1.3: Comparison of Homo sapiens p62/SQSTM1 protein (A) and Drosophila 
melanogaster Ref(2)P protein (B) with conserved domains. Highlighted are the PB1 
domain (green), the ZZ domain (yellow) and the UBA domain (red).  
Figure 1.4: Comparison of Homo sapiens VCP protein (A) and Drosophila melanogaster 
TER94 protein (B) with conserved domains. Highlighted are the CDC48 domain (blue), 
the AAA ATPase domain (purple), the ATPase AAA domain (green), the Lid domain 














1.7 Research Goals  
 
While TARDBP, TBK1, p62/SQSTM1 and VCP have been suggested as candidate 
genes in the development of neurodegenerative diseases, their role in disease progression 
has not been fully characterized. This study aims to study the effects of genes directly 
related to ALS and PD and to study biological outcomes of the altered expression of such 
significant genes that associate and interact. This study aims to examine the effects of 
altered ALS gene expression in combination with altered PD gene activity and to 
investigate the consequences of altered ALS gene expression in the dopaminergic 
neurons. By manipulating gene expression of selected genes in D. melanogaster, 
researchers may gain insight into how their alteration, both the overexpression and 
inhibition, impacts Drosophila lifespan, motor functions, and, in complementary 
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Chapter 2 – Methodology 
 
2.1 Drosophila melanogaster stocks and culture  
 
Drosophila melanogaster was maintained on a standard media comprised of 65 
g/L cornmeal, 50 ml/L fancy grade molasses, 10 g/L yeast and 5.5 g/L agar which was 
then treated with 2.5 ml propionic acid and 5 ml of 0.1 g/ml methylparaben. This mixture 
was then allowed to solidify at the bottom of vials and stored in 4 to 6º C until use. Stocks 
were stored at room temperature (~ 21º C) due to limited incubator space.  
 
2.2 Longevity Assay 
 
Critical class male progeny were collected daily and placed in vials with fresh 
medium. A sample size of 300 males was collected in total and stored at 25º C for the 
duration of the experiment. The flies were scored every two days to examine if any death 
had occurred. A fly was considered dead when no movement was observed. Males were 
transferred onto fresh media every four days to obtain a healthy environment. The data 
was analyzed using the Graphpad Prism 8 software (Graphpad Software Inc.) with a 
comparison of the survival curves analyzed by the Log-rank (Mantel-Cox) test. 
Significance was determined at 95%, at a P-value less than or equal to 0.05 with 
Bonferroni correction. 
 
2.3 Locomotive Assay  
 
Critical class male progeny were collected within a 24-hour time period for a 
sample size of 70 male progeny. Critical class males were maintained in vials with ten 
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flies per vial, stored at 25º C, and placed on new medium once per week throughout the 
experiment. The climbing ability of critical class flies was carried out to examined the 
motor function of the flies over time. The analysis began one week after collection and 
then every seven days after until flies had a minimum climbing score for two consecutive 
weeks, or less than ten flies remained alive. Climbing ability was analyzed at the same 
time each week for consistency. For each genotype, the climbing ability of five cohorts 
was analyzed. For each cohort of 10 flies, ten trials were then carried out, which resulted 
in a total of 500 trials per genotype per week. To score the climbing ability of the flies a 
30 cm glass tube with a 1.5 cm diameter was used which was marked with five 2 cm 
sections starting from the bottom with the remainder of the glass tube left as a buffer zone 
(Todd & Staveley, 2004). The flies were scored based on the height that was reached on 
the tube after a ten second time period. A climbing index was then calculated as Climbing 
index = Σ nm/N, where n represents the number of flies at a given level, m is the score of 
the level (between 1 and 5) and N is the total number of flies climbed in that trial. The 
data was analyzed using the Graphpad Prism 8 software (Graphpad Software Inc.) Using 
this software, a nonlinear regression curve was produced with a 95% confidence interval, 
with the slope of each curve representing the rate of decline in climbing ability and the Y-
intercept representing the initial climbing ability. The curves were considered to be 







2.4 Scanning Electron Microscopy of the Drosophila eye 
 
The GMR-Gal4 transgenic line was used, which allowed expression of the 
paternally contributed transgenes in the eye of the fly. Critical class male progeny from 
each cross was collected, aged for 3 to 5 days post eclosion, and frozen at -80 °C, in order 
to sacrifice and preserve the flies before being placed on SEM studs. Studs were placed in 
a desiccator for at least 48 hours to dry. Using either the Mineral Liberation Analyzer FEI 
650F or the FEI Quanta 400 Scanning Electron Microscope, ten different eye images for 
each genotype were taken to visualise the left eye of the fly. The ten images were selected 
based on the quality and clarity of the image. Images were then examined using the 
National Institutes of Health (NIH) ImageJ software for the extent of eye development, 
counting both the number of ommatidia and bristles, this data was then analyzed using 












Chapter 3 – Modelling Amyotrophic Lateral Sclerosis in Drosophila melanogaster 
Through Alteration of TBPH 
3.1 Introduction  
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease 
characterized by the loss of upper and lower motor neurons within the spinal cord, brain 
stem and motor cortex. Eventually, this gradual deterioration of motor neurons results in 
muscle weakness and atrophy (Scotter, Chen, & Shaw, 2015). Although the progression 
of ALS remains poorly understood; there are a number of candidate genes of great 
interest that can contribute to the development of the disease. One of the major ALS-
assoicated genes, TARDBP, encodes the multifunctional DNA/RNA binding protein 
TDP-43, known as TBPH in Drosophila. The TDP-43 protein is located primarily in the 
nucleus of neurons, glial cells, and muscle cells but can shuttle to the cytoplasm up to a 
level of 30% (Mackenzie & Rademakers, 2008; Neumann et al., 2007). In the nucleus, 
TDP-43 regulates RNA splicing and modulates microRNA biogenesis (Scotter et al., 
2015). While in the cytoplasm of neurons, TDP-43 is a critical component of dendritic 
and somatodendritic RNA transport granules, and exhibits a key role in neuronal 
plasticity through the regulation of local protein synthesis in dendrites (Scotter et al., 
2015; Xu, 2012). Events that can cause the TDP-43 protein to move into the cytoplasm 
are highly stress-related and include oxidative stress, endoplasmic reticulum stress, and 
heat stress (Buratti & Baralle, 2008). Once in the cytoplasm, TDP-43 can incorporate into 
stress granules that possibly then lead to its pathological transformation. These abnormal 
TDP-43 cytoplasmic aggregates have multiple modifications, including 
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hyperphosphorylation, ubiquitination and cleaving, preventing TDP-43 from crossing the 
nuclear membrane (Gasset-rosa et al., 2019; Buratti & Baralle, 2008). This TDP-43 
shuttling event has been suggested to be a critical component in disease pathogenesis (Lu 
et al., 2016), as abnormal cytoplasmic aggregates have been reported within the neurons 
and glia in over 90% of ALS cases (Ling, Polymenidou, & Cleveland, 2013; Gasset-Rosa 
et al., 2019). However, this shuttling event is not the only factor to consider in TDP-43 
pathology. The interactions and roles which TDP-43 has in the mitochondria are 
important to consider, as mitochondrial damage and impaired mitophagy are known to be 
associated with many neurodegenerative diseases. TDP-43 is known to be associated with 
the mitochondria and mitochondrial defects, with TDP-43 pathology becoming an 
emerging topic (Davis et al., 2018; Gautam, Xie, Kocak, & Ozdinler, 2019). Studies have 
demonstrated mitochondrial impairment by TDP-43 to be an early event, resulting in cell 
death (Wang et al., 2019). There are many unanswered questions involving the specific 
role that TDP-43 plays in ALS pathogenesis; however, it is clear that the loss-of-function 
of TDP-43 in the nucleus is a substantial factor in disease progression (Ling et al., 2013; 
Van Deerlin et al., 2008). A further investigation must occur to understand the cellular 
mechanisms that TDP-43 plays in disease.  
 
The TARDBP gene has been highly conserved throughout evolutionary history. A 
comparison of human TDP-43 and D. melanogaster TBPH proteins reveals the TDP-43 
N-terminal domain as a highly conserved domain, as well as two highly conserved motifs, 
RNA recognition motif 1 (RRM1) and RNA recognition motif 2 (RRM2). The degree of 
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evolutionary conservation suggests a highly conserved function for TDP-43. Thus 
exploration of the effects of altered TARDBP expression in D. melanogaster may provide 
insights into the pathology of ALS in humans. In this study, inhibition of TBPH in D. 
melanogaster are used to mimic human conditions, examining the effects on lifespan and 
locomotor ability. The overexpression of TBPH was also examined to investigate the 
biological impacts on D. melanogaster.  
 
3.2 Materials and Methods  
 
3.2.1 Drosophila melanogaster stocks and culture  
 
All Drosophila stocks were obtained from the Bloomington Drosophila Stock 
Center at Indiana University (IN, USA). See Table 1.1 for list of genotypes used. See 
Chapter 2, section 2.1 for detail of D. melanogaster stocks and culture. 
 
3.2.2 Longevity Assay 
The survival of D. melanogaster was analyzed to examine the median lifespan of 
experimental flies in comparison to control flies. See Chapter 2, section 2.2 for full 
longevity assay methods.   
 
3.2.3 Locomotive Assay 
 The motor function of D. melanogaster was analyzed to examine the locomotor 
function over time of experimental flies in comparison to control flies. See Chapter 2 
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section 2.3 for full locomotive assay methods.   
 
3.2.4 Scanning Electron Microscopy of the Drosophila eye 
Eye analysis of D. melanogaster was used to determine the effects of gene 
manipulation. See Chapter 2 section 2.4 for full methods on eye experiments.   
 
Table 1.1: Genotypes and location of expression patterns used in the analysis of altered 








Control Lines    
UAS-lacZ --- 2 Brand et al., 1993 
Transgene Lines    
GMR-Gal4 Eye 2 Freeman, 1996 
arm-Gal4 Ubiquitous  2 Sanson et al., 1996 




3 Inamdar et al., 
2014 
ddc-Gal4HL4.3D Dopaminergic and 
serotonergic neuron 
2 Li et al., 2000 
ddc-Gal4HL4.36 Dopaminergic and 
serotonergic neuron 
3 Li et al., 2000 
D42-Gal4 Motor neuron 3 Parkes et al., 1998 
Responder Lines    
UAS-TBPHEY10530 --- 2 Bellen et al., 2011 
UAS-TBPH-
RNAiHMS05194 
--- 3 Perkins et al., 2015 
UAS-TBPH-
RNAiHMS01932 







3.3.1 Inhibition of TBPH decreases median lifespan and climbing ability  
An investigation of how the inhibition of TBPH impacts the lifespan and climbing 
ability of D. melanogaster has shown that one of the two inhibition transgenes has a 
significantly more significant impact than the other. Several TBPH inhibition lines were 
selected to investigate the consequences of both to the fly. The TBPH RNAi transgene, 
UAS-TBPH-RNAiHMS01932, has been shown to significantly reduce median lifespan when 
expressed with the ubiquitous transgene arm-Gal4 (Figure 2.1) and the pan-neuronal 
transgene elav-Gal4 (Figure 2.2) when compared to the control (UAS-lacZ). When 
expressed through the elav-Gal4 transgene, inhibition of TBPH via UAS-TBPH-
RNAiHMS01932 resulted in extremely poor viability of critical class males. The inhibition of 
TBPH, via UAS-TBPH-RNAiHMS01932, significantly reduced median lifespan (Figure 2.3a), 
and climbing ability over time (Figure 2.3b) when expressed with the motor neuron-
specific transgene D42-Gal4. When expressed through the dopaminergic neuron-specific 
transgene TH-Gal4, inhibition of TBPH significantly decreased median lifespan (Figure 
2.4a), but not climbing ability (Figure 2.4b). The TBPH inhibition through the neuron-
specific transgene ddc-Gal4HL4.3D greatly reduced median lifespan (Figure 2.5a) and 
climbing ability over time (Figure 2.5b). However, when expressed through the neuron-
specific transgene ddc-Gal4HL4.36, inhibition of TBPH did not provide any statistically 
significant changes in median lifespan (Figure 2.6a), or to climbing ability over time 
(Figure 2.6b) when compared to the control (UAS-lacZ). 
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3.3.2 Inhibition of TBPH decreases ommatidia and bristle count  
 The developmental pattern of the Drosophila compound eye is a highly regulated 
and specific event with each eye being comprised of approximately 800 ommatidia under 
standard development. Once the pattern of ommatidia are laid down, the bristles are 
generated later as a form of protection for the ommatidia. Impairment in this process may 
result in characteristic phenotypes as a consequence, such as changes in the number of 
ommatidia and bristles. To investigate such phenotypic changes in D. melanogaster, the 
eye-specific transgene GMR-Gal4 has been used. The TBPH inhibition, through the 
directed expression of UAS-TBPH-RNAiHMS01932, when expressed in the developing eye of 
D. melanogaster has shown to significantly reduce the quantity of ommatidia (Figure 
2.8a) and interommatidial bristles (Figure 2.8b) when compared to the control (UAS-
lacZ). 
 
3.3.3 Overexpression of TBPH decreases median lifespan and climbing ability 
When TBPH is overexpressed through the action of the pan-neuronal transgene, 
elav-Gal4 median lifespan is significantly reduced (Figure 2.2). When TBPH was 
overexpressed through the dopaminergic neuron-specific transgene TH-Gal4, median 
lifespan (Figure 2.4a) and climbing ability over time (Figure 2.4b) are reduced. As well, 
when TBPH is overexpressed through the motor neuron-specific transgene D42-Gal4, 
median lifespan (Figure 2.3a) and climbing ability over time (Figure 2.3b) are 









Figure 2.1: Altered expression of TBPH directed through the arm-Gal4 transgene affects 
lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using the log-
rank test with Bonferroni correction. Error bars represent standard error of the mean. 
Genotypes are as follows: arm-Gal4;UAS-lacZ (n=284), arm-Gal4;UAS-TBPHEY10530 
















Figure 2.2: Altered expression of TBPH directed through the elav-Gal4 transgene affects 
lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using the log-
rank test with Bonferroni correction. Error bars represent standard error of the mean. 
Genotypes are as follows: elav-Gal4;UAS-lacZ (n=298), elav-Gal4;UAS-TBPHEY10530 

































Figure 2.3: Altered expression of TBPH directed through the D42-Gal4 transgene affects 
longevity and climbing ability. A: Longevity assay of Drosophila melanogaster males 
displaying altered TBPH expression in the motor neurons. Longevity is depicted by 
percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
D42-Gal4;UAS-lacZ (n=273), D42-Gal4;UAS-TBPHEY10530 (n=274), D42-Gal4;UAS-
TBPH-RNAiHMS01932 (n=290), D42-Gal4;UAS-TBPH-RNAiHMS05194 (n=264). B: Locomotor 
assay of D. melanogaster males displaying altered TBPH expression in the motor 
neurons. Climbing ability was determined by a nonlinear curve fit (CI=95%). Error bars 






























Figure 2.4: Altered expression of TBPH directed through the TH-Gal4 transgene affects 
longevity and climbing ability. A: Longevity assay of Drosophila melanogaster males 
displaying altered TBPH expression in the dopaminergic neurons. Longevity is depicted 
by percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: TH-
Gal4;UAS-lacZ (n=290), TH-Gal4;UAS-TBPHEY10530 (n=263), TH-Gal4;UAS-TBPH-
RNAiHMS01932 (n=280), TH-Gal4;UAS-TBPH-RNAiHMS05194 (n=283). B: Locomotor assay of 
D. melanogaster males displaying altered TBPH expression in the dopaminergic neurons. 
Climbing ability was determined by a nonlinear curve fit (CI=95%). Error bars indicate 






Figure 2.5: Altered expression of TBPH directed through the ddc-Gal4HL4.3D transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered TBPH expression in the neurons. Longevity is depicted by 
percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
ddc-Gal4HL4.3D;UAS-lacZ (n=293), ddc-Gal4HL4.3D;UAS-TBPHEY10530 (n=271), ddc-
Gal4HL4.3D;UAS-TBPH-RNAiHMS01932 (n=298), ddc-Gal4HL4.3D;UAS-TBPH-RNAiHMS05194 
(n=296). B: Locomotor assay of D. melanogaster males displaying altered TBPH 
expression in the neurons. Climbing ability was determined by a nonlinear curve fit 


































Figure 2.6: Altered expression of TBPH directed through the ddc-Gal4HL4.36 transgene 
does not affect longevity and climbing ability. A: Longevity assay of Drosophila 
melanogaster males displaying altered TBPH expression in the neurons. Longevity is 
depicted by percent survival. Significance is P <0.05 using the log-rank test with 
Bonferroni correction. Error bars represent standard error of the mean. Genotypes are as 
follows: ddc-Gal4HL4.36;UAS-lacZ (n=284), ddc-Gal4HL4.36;UAS-TBPH-RNAiHMS01932 
(n=263). B: Locomotor assay of D. melanogaster males displaying altered TBPH 
expression in the neurons. Climbing ability was determined by a nonlinear curve fit 























                    





Figure 2.7: Directed alteration of the TBPH gene expression using eye-specific transgene 
GMR-Gal4 in Drosophila. Scanning electron micrographs of A: GMR-Gal4;UAS-lacZ, B: 















Figure 2.8: Biometric analysis of Drosophila compound eye under direct eye expression 
of TBPH through the GMR-Gal4 transgene. Inhibition of TBPH through UAS-TBPH-
RNAiHMS01932 caused a significant decrease in both (A) ommatidia number and (B) bristle 













3.4 Discussion  
 
 The development and progression of ALS remains unclear and the desire to reach 
a greater understanding of this provides the incentive for an ongoing field of scientific 
research. Of great importance, as the prevalence of the disease continues to increase, the 
search for this understanding may lead to the development of treatments and therapies. 
Altered expression of TBPH produced a significant effect upon the longevity, locomotor 
function and neurodevelopment in D. melanogaster. Critical class flies that inhibited 
function through the expression of UAS-TBPH-RNAiHMS01932 display a reduction in median 
lifespan and of locomotor function over time. This reduction in longevity caused by the 
loss-of-function of TBPH suggests that the function of this gene product may play a 
substantial role in cell survival and death. Specifically, when inhibition of TBPH is 
accomplished through the activity of the pan-neuronal transgene elav-Gal4, viability is 
significantly reduced, and survival to adulthood is extremely poor. Certainly, the reduced 
rate of eclosion may be due to the toxic effects produced by of the loss of TBPH function 
in Drosophila. The most significant reduction in median lifespan and motor function is 
seen when TBPH function is inhibited in the motor neuron, through the D42-Gal4 
transgene. This significant reduction in median lifespan and motor ability when TBPH 
expression is altered corresponds with the characteristic loss of motor neurons associated 
with ALS, making the inhibition of TBPH in the motor neuron a promising model of 
neurodegenerative disease. Studies have observed the impacts that TDP-43 has in the 
motor neuron, demonstrating the severe impact that loss-of-function has to aspects such 
as microglia morphology (Spiller et al., 2018), axon degeneration, and TDP-43 median 
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splicing repression (Donde et al., 2019). In regards to Drosophila, loss-of-function of 
TBPH in the motor neurons has been shown to affect the neuromuscular junctions, 
displaying anatomical defects such as a reduction in axonal branches and synaptic 
boutons located within the muscles (Feiguin et al., 2009). The role that TDP-43 has in the 
motor neuron appears to be essential in at least certain forms of ALS pathology, with the 
TDP-43 shuttling event and functions in the mitochondria being a critical factor in ALS 
development and progression.  
 
The development of the compound eye of Drosophila is a highly regulated and 
specifically controlled process. Critical class flies that expressed the loss-of-function of 
UAS-TBPH-RNAiHMS01932 displayed a significant reduction in the quantity of both the 
ommatidia and interommatidial bristles. Often, these characteristic phenotypes are due to 
an impairment during the development of the Drosophila eye and may reveal a specific 
defect during neurodevelopment. Regarding the expression of TDP-43 in the Drosophila 
eye, one study has shown through whole-genome microarrays, highly upregulated and 
downregulated genes from a family of G-protein coupled receptors (GPCRs), the 
methuselah family, known to be involved in regulating adult lifespan. Other genes 
identified in this study played a role in regulating the mitochondria as well as oxidative 
cellular processes (Zhan, Hanson, Kim, Tare, & Tibbetts, 2013). As TBPH inhibition 
compromised the phenotype of the Drosophila eye insights from the neurodegenerative 
process may be made. The inhibition of TBPH appears to mimic the suggested pathology 
of ALS and thus making this a promising model of neurodegenerative disease.  
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The overexpression of TBPH influenced critical class flies only when expressed 
through a subset of the specific Gal4 transgenes. When overexpressed through the pan-
neuronal directing transgene elav-Gal4, flies displayed a reduction in median lifespan. 
Overexpression of TBPH through the dopaminergic neuron-specific transgene TH-Gal4 
and the neuron-specific transgene ddc-Gal4HL4.3D displayed a significant reduction in 
median lifespan. Locomotor ability was not altered by TBPH overexpression when 
expressed through either TH-Gal4 or ddc-Gal4HL4.3D transgenes. However, locomotor 
function was significantly reduced when TBPH was overexpressed through the activity of 
the motor neuron-specific transgene D42-Gal4, but median lifespan was minimally 
impacted. Previous studies have shown that the overexpression of TDP-43 has the ability 
to induce neurotoxicity as well as early death in the fly (Li et al., 2010; Voigt et al., 2010; 
Zhan et al., 2013). However, some have suggested that the degeneration caused by the 
overexpression of TDP-43 is not through the “classical” programmed cell death pathways 
(Hanson, Kim, Wassarman, & Tibbetts, 2010; Zhan et al., 2013). A further investigation 
into the consequences of the overexpression of TDP-43 is required to fully understands its 
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Chapter 4 – Modelling Amyotrophic Lateral Sclerosis in Drosophila melanogaster 
Through Alteration of IK2 
 
4.1 Introduction  
 
The TANK-binding kinase 1 (TBK1) is one of the most recently identified genes 
that contributes to inherited forms of ALS. TBK1, also known as NAK or T2K, encodes a 
multifunctional serine/threonine kinase that belongs to the IkappaB kinase-like 2 (IK2) 
family of kinases. This group of related proteins has been demonstrated to act as essential 
regulators in the responses regulating inflammation, immunity, apoptosis and autophagy 
(Heo, Ordureau, Paulo, Rinehart, & Harper, 2015; Larabi et al., 2013; Lazarou et al., 
2015). In the cell, the location of TBK1 is in the cytoplasm, cytosol, nucleoplasm and the 
endosome membrane, where it has significant roles in both the immune system and 
autophagy (Ahmad, Zhang, Casanova, & Sancho-Shimizu, 2016; Oakes, Davies, & 
Collins, 2017). With regards to the role that TBK1 has in the process of autophagy, TBK1 
is activated through the phosphorylation of the receptor proteins that control autophagy. 
These autophagic receptors include sequestosome 1, also known as p62/SQSTM1, and 
optineurin (OPTN) (Nguyen, Thombre, & Wang, 2018; Richter et al., 2016). These 
autophagy-related receptors play a role related to their association with autophagy-related 
proteins, which can recognize both specific and non-specific cargo, that are then to be 
degraded then recycled via the activity of the lysosomes (Ahmad et al., 2016; Oakes et 
al., 2017). The ability of autophagy-related proteins to recognize specific cargo is through 
the activity of p62/SQSTM1 and OPTN and the ability of proteins to bind to ubiquitin 
residues on the cargo to be targeted. Once bound, this enables the process by which the 
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ubiquitinated protein product to be sent for degradation (Ahmad et al., 2016; Oakes et al., 
2017). As proteins such as p62/SQSTM1 and OPTN have critical roles in autophagy 
processes, it is vital to explore their role of these in the development of neurodegenerative 
disease.  
 
Studies have shown that mutations in TBK1 result in the impairment of autophagy, 
which in turn contributes to the formation of protein aggregates and thus disease 
pathology. At least a partial loss of TBK1 has been reported to result in the progression of 
ALS and frontotemporal dementia (FTD) (Oakes et al., 2017). Recent studies have shown 
that loss of TBK1 results in both embryonic death and neurodegeneration, as a result of 
activated Receptor-interacting serine/threonine-protein kinase 1(RIPK1), an enzyme that 
is a crucial regulator in cell survival and death. Specifically, RIPK1 binds to the TBK1 
substrate OPTN and functions in various cellular pathways involved in cell survival and 
death (Ito et al., 2016; Xu et al., 2018; Yu & Cleveland, 2018). This activated RIPK1 is 
caused by a mutation in TBK1, with the inhibition of RIPK1 shown to prevent TBK1 
knockdown, embryonic lethality and neurodegeneration (Xu et al., 2018; Yu & 
Cleveland, 2018). Therefore, for both healthy development and to reduce the risk of 
neurodegeneration, RIPK1 kinase activity must be inhibited (Xu et al., 2018; Yu & 
Cleveland, 2018). As TBK1 is a newly identified gene, and much remains unknown about 
the role of it in neurogenerative disease, thus making it an excellent candidate gene to 
research. However, not only mutations in TBK1 result in impaired autophagy but loss of 
function mutations in p62/SQSTM1 and OPTN, two autophagy receptors for TBK1 have 
been reported to cause abnormal autophagy (Ahmad et al., 2016; Oakes et al., 2017). 
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Therefore, it is essential to investigate the functions of TBK1 and its autophagy receptors, 
and to manipulate their expression in a selected set of neurons. 
 
The TBK1 gene and the IK2 family of genes have been highly conserved 
throughout evolutionary history. A comparison of human TBK1 and D. melanogaster IK2 
proteins reveals three highly conserved domains: 1) the P kinase domain; 2) a ubiquitin-
like domain; and 3) the coiled-coil domain 1 (CCD1). The degree of evolutionary 
conservation suggests a highly conserved function for TBK1/IK2. Thus exploration of the 
effects of altered IK2 expression in D. melanogaster should be expected to provide 
insights into the pathology of ALS in humans. In this study, both the overexpression and 
inhibition of IK2 in D. melanogaster is used to mimic human conditions, examining the 
effects on lifespan and locomotor ability. 
 
4.2 Materials and Methods  
 
4.2.1 Drosophila melanogaster stocks and culture  
 
All Drosophila stocks were obtained from the Bloomington Drosophila Stock 
Center at Indiana University (IN, USA). See Table 2.1 for list of genotypes used. See 






3.2.2 Longevity Assay 
The survival of D. melanogaster was analyzed to examine the median lifespan of 
experimental flies in comparison to control flies. See Chapter 2, section 2.2 for full 
longevity assay methods.   
 
2.2.3 Locomotive Assay 
 The motor function of D. melanogaster was analyzed to examine the locomotor 
function over time of experimental flies in comparison to control flies. See Chapter 2, 
section 2.3 for full locomotive assay methods.   
 
2.2.4 Scanning Electron Microscopy of the Drosophila eye 
Eye analysis of D. melanogaster was used to determine the effects of gene 











Table 2.1: Genotypes and location of expression patterns used in the analysis of altered 
expression of IK2.   





Control Lines    
UAS-lacZ --- 2 Brand et al., 1993 
Driver Lines    
GMR-Gal4 Eye 2 Freeman, 1996 
arm-Gal4 Ubiquitous  2 Sanson et al., 
1996 
elav-Gal4 Pan neuronal 1 Lin & Goodman, 
1994 
TH-Gal4 Dopaminergic neuron 3 Inamdar et al., 
2014 
ddc-Gal4HL4.3D Dopaminergic and 
serotonergic neuron 
2 Li et al., 2000 
ddc-Gal4HL4.36 Dopaminergic and 
serotonergic neuron 
3 Li et al., 2000 
D42-Gal4 Motor neuron 3 Parkes et al., 1998 
Responder Lines    
UAS-IK2EY09774 --- 2 Bellen et al., 2004 
UAS-IK2-RNAiHMS01188 --- 3 Perkins et al., 
2015 













4.3.1 Overexpression of IK2 decreases median lifespan and climbing ability over 
time  
When IK2 is overexpressed D. melanogaster median lifespan, and climbing ability 
over time is greatly influenced. Overexpression of IK2 significantly reduces median 
lifespan when expressed through the ubiquitous transgene arm-Gal4 (Figure 3.1) and the 
pan-neuronal transgene elav-Gal4 (Figure 3.2). IK2 overexpression through the motor 
neuron-specific transgene D42-Gal4 significantly reduced median lifespan (Figure 3.3a) 
and climbing ability over time (Figure 3.3b) compared to the control (UAS-lacZ). 
IK2 overexpression through the dopaminergic neuron-specific transgene TH-
Gal4 significantly reduced median lifespan (Figure 3.4a). However, the climbing ability 
of D. melanogaster was not influenced (Figure 3.4b). Notably, it is worth mentioning 
that IK2 overexpression through TH-Gal4 provided very poor viability of critical class 
males. When IK2 is overexpressed through the neuron-specific transgenes ddc-
Gal4HL4.3D and ddc-Gal4HL4.36 no critical class male progeny survived to adulthood.  
 
4.3.2 Inhibition of IK2 increases median lifespan and decreases climbing ability in 
the motor neuron over time 
 An investigation of the consequences of inhibition of IK2 upon the median 
lifespan and climbing function of D. melanogaster was carried out using 
two IK2 inhibition transgenes, UAS-IK2-RNAiHMS01188 and UAS-IK2-RNAiGL00160. Two 
IK2 inhibition lines were selected to investigate the consequences of both on the fly. 
Both IK2 RNAi transgenes increased median lifespan when expressed through the 
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ubiquitous transgene arm-Gal4 (Figure 3.1) and the motor neuron-specific 
transgene D42-Gal4 (Figure 3.3a), while decreasing median lifespan when expressed 
through the pan-neuronal transgene elav-Gal4 (Figure 3.2) when compared to the control 
(UAS-lacZ). When expressed through the dopaminergic neuron-specific transgene TH-
Gal4 (Figure 3.4a), as well as the neuron-specific transgene ddc-Gal4HL4.3D (Figure 3.5a), 
the IK2 RNAi transgene UAS-IK2-RNAiGL00160 resulted in an increased median lifespan, 
while the IK2 RNAi transgene UAS-IK2-RNAiHMS01188 lead to a reduction in median 
lifespan. Both IK2 inhibition transgenes impacted climbing ability over time when 
expressed through the motor neuron-specific transgene D42-Gal4 (Figure 3.3b), leading 
to a significant reduction in motor function. Inhibition of IK2 through the dopaminergic 
neuron-specific transgene TH-Gal4 did not significantly alter climbing ability over time 
(Figure 3.4b) when compared to the control (UAS-lacZ). Expression of the IK2 inhibition 
line UAS-IK2-RNAiHMS01188 through the neuron-specific transgene ddc-Gal4HL4.3D did not 
significantly influence climbing ability over time (Figure 3.5b); however, the inhibition 
line UAS-IK2-RNAiGL00160 lead to a significant reduction in climbing ability over time 
(Figure 3.5b) when compared to the control (UAS-lacZ). 
  
4.3.3 Inhibition of IK2 decreases ommatidia and bristle count 
 The developmental pattern of the Drosophila compound eye is a highly regulated 
and specific event. Once the ommatidia are laid down, the bristles come next as a form of 
protection for the ommatidia. Impairment in this process may result in characteristic 
phenotypes as a consequence, such as changes in the number of ommatidia and bristles. 
The eye-specific transgene GMR-Gal4 is used to investigate such phenotypic changes in 
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the compound eye of D. melanogaster. Expression of the IK2 inhibition transgene UAS-
IK2-RNAiHMS01188 in the developing eye of D. melanogaster has shown to significantly 
reduce the number of ommatidia (Figure 3.7a) and interommatidial bristles (Figure 3.7b) 





















Figure 3.1: Altered expression of IK2 directed through the arm-Gal4 transgene affects 
lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using the log-
rank test with Bonferroni correction. Error bars represent standard error of the mean. 
Genotypes are as follows: arm-Gal4;UAS-lacZ (n=284), arm-Gal4;UAS-IK2EY09774 








Figure 3.2: Altered expression of IK2 directed through the elav-Gal4 transgene affects 
lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using the log-
rank test with Bonferroni correction. Error bars represent standard error of the mean. 
Genotypes are as follows: elav-Gal4;UAS-lacZ (n=298), elav-Gal4;UAS-IK2EY09774 




























Figure 3.3: Altered expression of IK2 directed through the D42-Gal4 transgene affects 
longevity and climbing ability. A: Longevity assay of Drosophila melanogaster males 
displaying altered IK2 expression in the motor neurons. Longevity is depicted by percent 
survival. Significance is P <0.05 using the log-rank test with Bonferroni correction. Error 
bars represent standard error of the mean. Genotypes are as follows: D42-Gal4;UAS-lacZ 
(n=273), D42-Gal4;UAS-IK2EY09774 (n=267), D42-Gal4;UAS-IK2-RNAiHMS01188 (n=330), 
D42-Gal4;UAS-IK2 RNAiGL00160(n=321). B: Locomotor assay of D. melanogaster males 
displaying altered IK2 expression in the motor neurons. Climbing ability was determined 
































Figure 3.4: Altered expression of IK2 directed through the TH-Gal4 transgene affects 
longevity and climbing ability. A: Longevity assay of Drosophila melanogaster males 
displaying altered IK2 expression in the dopaminergic neurons. Longevity is depicted by 
percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: TH-
Gal4;UAS-lacZ (n=290), TH-Gal4;UAS-IK2EY09774 (n=103), TH-Gal4;UAS-IK2-
RNAiHMS01188 (n=280), TH-Gal4;UAS-IK2 RNAiGL00160(n=324). B: Locomotor assay of D. 
melanogaster males displaying altered IK2 expression in the dopaminergic neurons. 
Climbing ability was determined by a nonlinear curve fit (CI=95%). Error bars indicate 




Figure 3.5: Altered expression of IK2 directed through the ddc-Gal4HL4.3D transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered IK2 expression in the neurons. Longevity is depicted by percent 
survival. Significance is P <0.05 using the log-rank test with Bonferroni correction. Error 
bars represent standard error of the mean. Genotypes are as follows: ddc-Gal4HL4.3D;UAS-
lacZ (n=293), ddc-Gal4HL4.3D;UAS-IK2-RNAiHMS01188 (n=300), ddc-Gal4HL4.3D;UAS-IK2 
RNAiGL00160(n=314). B: Locomotor assay of D. melanogaster males displaying altered IK2 
expression in the neurons. Climbing ability was determined by a nonlinear curve fit 
























         
 
Figure 3.6: Directed IK2 gene expression using eye-specific transgene GMR-Gal4 in 
Drosophila. Scanning electron micrographs of A: GMR-Gal4;UAS-lacZ, B: GMR-










Figure 3.7: Biometric analysis of Drosophila compound eye under direct eye expression 
of IK2 though the GMR-Gal4 transgene. Inhibition of IK2 causes significant decrease in 












 Understanding the development and the progression of neurodegenerative diseases 
such as ALS and PD is a critical goal of modern research. As a recently discovered ALS 
gene, TBK1, there is much left unknown with regards to its functions and roles in 
neurodegeneration, making it an excellent candidate gene to investigate in model 
organisms. Human TBK1 is a serine/threonine-protein kinase from the IkappaB kinases 
(IKKs) family (Heo et al., 2015). A member of the IKK family and the Drosophila 
homologue of TBK1, IK2 has been shown to influence longevity of the organism, 
locomotor function and neuronal development when manipulated. Critical class flies 
overexpressing IK2 displayed reduced median lifespan when directed by selected Gal4 
transgenes, with a considerable reduction seen when IK2 was overexpressed through the 
motor neuron-specific transgene D42-Gal4 and the dopaminergic neuron-specific 
transgene TH-Gal4. Interestingly, when IK2 was overexpressed through the activity of 
TH-Gal4, the viability of critical class males was poor. This lethality seen by the gain-of-
function of IK2 suggests that normal function is essential to provide viability. Attempts 
were made to examine the effects of the overexpression of IK2 through the neuron-
specific transgenes ddc-Gal4HL4.3D and ddc-Gal4HL4.36; however critical class males did 
not survive to adulthood. The reduction in lifespan, as well as the multiple cases of 
impaired viability, suggest that IK2 plays a substantial role in cellular pathways that 
govern cell survival and death. The overexpression of IK2 greatly influenced motor 
ability throughout life. Overexpression of IK2 directed through the motor neuron-specific 
transgene D42-Gal4, and the dopaminergic neuron-specific transgene TH-Gal4 leads to a 
phenotype that displayed a minimal reduction in climbing ability overtime, at the least. 
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The overexpression of IK2 appears to mimic aspects of the pathology of ALS. As ALS is 
a motor neuron disease, the reduction in median lifespan and a minimal decline in motor 
function observed when IK2 is overexpressed through the activity of the motor neuron-
specific transgene D42-Gal4 produces an imperfect model of neurodegenerative disease.  
 
Much is still left unclear with regards to the mechanisms by which alteration to 
the activity of TBK1 contributes to the progression of neurodegenerative disease. 
However, studies have shown the importance of IK2 in Drosophila with regards to the 
process of dendrite pruning, a highly controlled procedure required for the development 
of neurons (Lee, Jan, & Jan, 2009). During neurodevelopment, specific Drosophila 
sensory neurons undergo a “pruning” of the dendrite metamorphosis before the time that 
adult dendrites generate. Throughout this process, the individual Drosophila undergo 
extensive neuronal remodeling where the IK2 gene, among others, play vital roles (Lee et 
al., 2009; Lin et al., 2015). The reduced viability observed when IK2 has been 
overexpressed through the activity of certain transgenes may be partially explained, at the 
least, by impaired neuronal development. Furthermore, the protein product of IK2 is a 
component in the organization of the cytoskeleton for mRNA localization during 
oogenesis (Lee et al., 2009; Shapiro & Andreson, 2006), where the IK2 protein along 
with Spindle-F proteins form a complex to play a substantial role during oogenesis in the 
regulation of cytoskeleton dynamics (Dubin-bar et al., 2008). Further investigations into 
the altered expression of TBK1 is required to more fully understand the role of this key 
gene in neurodegeneration. 
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The effects of the inhibition of IK2 seem to produce varied results. Both IK2  
inhibition experimental transgenes significantly increased lifespan when directed by the 
ubiquitous transgene arm-Gal4, while the same inhibition lines decreased lifespan when 
expressed through the pan-neuronal transgene elav-Gal4. Interestingly, when inhibited 
through the motor neuron-specific transgene D42-Gal4 both RNAi transgenes increased 
median lifespan, while reducing locomotor function over time. When the two IK2 
inhibition transgenes are expressed under control of the dopaminergic neuron-specific 
transgene TH-Gal4 and the neuron-specific transgene ddc-Gal4HL4.3D is when distinct 
differences are observed. When expressed through TH-Gal4 and ddc-Gal4HL4.3D, the IK2  
RNAi transgene, UAS-IK2-RNAiHMS01188 results in a much more reduced median lifespan, 
while when expressed through these same transgenes, the other IK2 inhibition transgene, 
UAS-IK2-RNAiGL00160, leads to a significant increase in median lifespan. Climbing ability 
was reduced for both forms of IK2 inhibition when expressed through all transgenes. The 
varied results of these experiments may suggest that one of the two IK2 inhibition 
transgenes used may have another, off-target hit to result in the median lifespan and 
locomotor function of the fly altered, while the other IK2 inhibition transgene may be 
functioning, as usual, causing actual inhibition of IK2. However, not only does IK2 
inhibition impact median lifespan and climbing ability, but also the development of the 
Drosophila compound eye. Critical class flies that expressed inhibition of IK2 through 
UAS-IK2-RNAiHMS01188 displayed a significant reduction in the quantity of both the 
ommatidia and bristle counts. These characteristic phenotypes are often due to an 
impairment in the development of the Drosophila eye, and thus may suggest an impact on 
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neurodevelopment. As human TBK1 is a relatively new ALS gene, more experiments 
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Chapter 5 - Modelling Human Neurodegenerative Disease Through Alteration of 
p62/Ref(2)P in Drosophila melanogaster 
 
5.1 Introduction 
 The elucidation of the cellular mechanisms that are altered during the progression 
of neurodegenerative diseases, such as ALS and Parkinson Disease, is an ongoing subject 
of current research. The protein, sequestosome1, which is also known as p62 
(p62/SQSTM1), has been suggested to be a potential contributor to in the pathogenesis of 
a number of neurodegenerative diseases (Ma, Attarwala, & Xie, 2019). The p62/SQSTM1 
protein is a multifunctional scaffold/adaptor protein encoded by the p62/SQSTM1 gene 
(Bartolome, Esteras, Martin-requero, & Boutoleau, 2017). Alternatively designated as 
“Refractory to Sigma P” (Ref(2)P) in Drosophila, p62/SQSTM1 is involved in various 
aspects of selective autophagy - such as mitophagy, the ubiquitin-proteasome system 
(UPS) and in some signal transduction pathways (Bitto et al., 2014). The p62/SQSTM1 
protein is localized throughout the cell in the cytoplasm, in the cytosol, and the 
endoplasmic reticulum, among other places such as autophagosomes, aggresomes, and 
autolysosomes, as this protein functions during the process of autophagy (Liu et al., 2016; 
Matsumoto, Shimogori, Hattori, & Nukina, 2015). The role which p62/SQSTM1 has in 
autophagy is critical as it seems to regulates the removal of protein aggregates and 
damaged organelles through the activities of several of its many functional domains (Bitto 
et al., 2014). Structurally the p62/SQSTM1 protein has many functional domains, several 
of which are essential to autophagic activities. These domains include 1) the Phox and 
Bem1 (PB1) domain; 2) the LC3 interacting region (LIR) domain; and 3) the UBA 
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domain at the C-terminus (Liang & Guan, 2017). During autophagy, the LIR domain and 
the UBA domains of p62/SQSTM1 have vital roles in the pathway (Hou et al., 2019; 
Johansen & Lamark, 2011; Ma, Attarwala, & Xie, 2019), as p62/SQSTM1 promotes 
autophagic degradation by binding to LC3 via its LIR region (Pankiv et al., 2007). The 
PB1 and the UBA domains function together to form protein aggregates (Bartlett et al., 
2011), and are known to be critical for mitochondrial clustering (Pimenta De Castro et al., 
2013). The UBA domain recognizes ubiquitinated protein aggregates, while the PB1 
domain sequesters these into inclusion bodies (Lee, Weihl, Lee, & Weihl, 2017). Other 
p62/SQSTM1 domains include the ZZ-type zinc finger domain, a domain capable of 
binding with the p38 mitogen-activated protein kinase, the TB domain, PEST sequences 
made up of the amino acids proline, glutamate, serine and threonine, and the KIR domain 
(Liang & Guan, 2017). As p62/SQSTM1 has multiple functional domains with various 
roles, investigating the p62/SQSTM1 gene in neurodegenerative disease may be of great 
advantage.  
 
In humans, p62/SQSTM1 can act as an indicator of autophagic flux as the protein 
accumulates when autophagy is inhibited. Similarly, it has been demonstrated that 
Ref(2)P behaves in the same manner, with accumulation of Ref(2)P levels in Drosophila 
when autophagy is genetically inhibited (Devorkin & Gorski, 2014). However, not only 
does p62/SQSTM1 function in quality control, but it is known to have roles in age-related 
diseases. Studies with a mouse model have shown that p62/SQSTM1 expression decreases 
as age increases, with protein knockdown reducing the lifespan and displaying premature 
signs of aging (Bitto et al., 2014). Mutations in p62/SQSTM1 are known to be associated 
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with ALS and frontotemporal dementia (FTD) (Bartolome et al., 2017). However, 
p62/SQSTM1 is not only associated with ALS and FTD, but it is known to be associated 
with some forms of Parkinson Disease through a defined role in mitophagy (Narendra, 
Kane, Hauser, Fearnley, & Youle, 2010; Yamada et al., 2019). Where during PINK1-
parkin-mediated mitophagy, p62/SQSTM1 among other adaptor proteins are recruited to 
damaged mitochondria (Xiao et al., 2017). Studies in Drosophila have demonstrated that 
loss-of-function of Ref(2)P results in poor locomotor function related to mitochondrial 
dysfunction and accumulation of mitochondrial DNA (Pimenta De Castro et al., 2013; 
Pimenta De Castro et al., 2012). Whereas in humans, knockdown of p62/SQSTM1 has 
shown to increase in both oxidative stress and mitochondrial damage and dysfunction 
(Bartolome et al., 2017; Bitto et al., 2014). Recent work has shown that p62/SQSTM1 
interacts with LRRK2, a PD-associated protein kinase as an autophagic receptor (Park, 
Han, Choi, Kim, & Park, 2016). Through the investigation of p62/SQSTM1 as a  
candidate gene we may gain further insight into our understanding of p62/SQSTM1 
function in both aging and neurodegenerative disease.  
 
The p62/SQSTM1 gene has been highly conserved throughout evolutionary 
history and a comparison of human and D. melanogaster p62/SQSTM1 proteins reveals 
three highly conserved domains, 1) the Phox and Bem1p (PB1) domain; 2) a zinc finger, 
ZZ type domain, as well as, 3) a ubiquitin associated domain (UBA). The degree of 
evolutionary conservation suggests a highly conserved function for p62/SQSTM1. Thus 
exploration of the effects of altered p62/SQSTM1 expression in D. melanogaster may 
provide insights into the pathology of ALS in humans. In this study, the inhibition 
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of p62/SQSTM1 in D. melanogaster is used to mimic human conditions, examining the 
effects on lifespan and locomotor ability.  
 
 
5.2 Materials and Methods  
 
5.2.1 Drosophila melanogaster stocks and culture  
 
All Drosophila stocks were obtained from the Bloomington Drosophila Stock 
Center at Indiana University (IN, USA). See Table 3.1 for list of genotypes used. See 
Chapter 2, section 2.1 for detail of D. melanogaster stocks and culture. 
 
5.2.2 Longevity Assay 
The survival of D. melanogaster was analyzed to examine the median lifespan of 
experimental flies in comparison to control flies. See Chapter 2, section 2.2 for full 
longevity assay methods.   
 
5.2.3 Locomotive Assay 
 The motor function of D. melanogaster was analyzed to examine the locomotor 
function over time of experimental flies in comparison to control flies. See Chapter 2, 
section 2.3 for full locomotive assay methods.   
 
5.2.4 Scanning Electron Microscopy of the Drosophila eye 
Eye analysis of D. melanogaster was used to determine the effects of gene 
manipulation. See Chapter 2, section 2.4 for full methods on eye experiments.   
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Table 3.1: Genotypes and location of expression patterns used in the analysis of altered 








Control Lines    
UAS-lacZ --- 2 Brand et al, 1993 
Driver Lines    
GMR-Gal4 Eye 2 Freeman, 1996 
arm-Gal4 Ubiquitous  2 Sanson et al., 
1996 




3 Inamdar et al., 
2014 
ddc-Gal4HL4.3D Dopaminergic and 
serotonergic 
neuron 
2 Li et al., 2000 
ddc-Gal4HL4.36 Dopaminergic and 
serotonergic 
neuron 
3 Li et al., 2000 
D42-Gal4 Motor neuron 3 Parkes et al., 1998 
Responder Lines    
UAS-Ref(2)P-
RNAiHMS00551 


















5.3.1 Inhibition of Ref(2)P increases median lifespan and decreases climbing ability  
 An investigation of the consequences of the inhibition of Ref(2)P upon the 
lifespan and climbing function over time of D. melanogaster was carried out using 
two Ref(2)P inhibition transgenes, UAS-Ref(2)P-RNAi HMS00551 and UAS-Ref(2)P-
RNAiHMS00938. Two Ref(2)P inhibition lines were selected to investigate the consequences 
of both on the fly. By examining Ref(2)P in D. melanogaster it was revealed that loss of 
function increased median lifespan. Expression of both Ref(2)P inhibition transgenes 
provided a significantly longer lifespan when expressed with the ubiquitous transgene 
arm-Gal4 (Figure 4.1) and the pan-neuronal transgene elav-Gal4 (Figure 4.2). Median 
lifespan was significantly increased when Ref(2)P was inhibited through the activity of 
the motor neuron-specific transgene D42-Gal4 (Figure 4.3a), and the dopaminergic 
neuron-specific transgene TH-Gal4 (Figure 4.4a) when compared to the control (UAS-
lacZ). When expressed through the neuron-specific transgenes ddc-GAL4HL4.3D (Figure 
4.5a) and ddc-GAL4HL4.36 (Figure 4.6a) inhibition of Ref(2)P resulted in a significant 
increase in median lifespan. Despite the significant influence upon longevity, inhibition 
of Ref(2)P decreases climbing ability over time in D. melanogaster. When expressed in 
the motor neuron-specific transgene D42-Gal4 (Figure 4.3b), the dopaminergic neuron-
specific transgene TH-Gal4 (Figure 4.4b), the inhibition of Ref(2)P through UAS-Ref(2)P-
RNAiHMS00938 significantly reduce climbing ability when compared to the control (UAS-
lacZ). When expressed through the neuron-specific transgene ddc-Gal4HLD.3D both 
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Ref(2)P inhibition transgenes led to a significant decrease in climbing ability (Figure 
4.5b). Expression of Ref(2)P inhibition via UAS-Ref(2)P-RNAiHMS00938 through the 
neuronal-specific transgene ddc-GAL4HL4.36 (Figure 4.6b) significantly reduced climbing 
ability when compared to the control (UAS-lacZ). 
 
5.3.2 Inhibition of Ref(2)P decreases ommatidia and bristle number  
 The developmental pattern of the Drosophila compound eye is a highly regulated 
and specific event. Once the ommatidia are laid down, the bristles come next as a form of 
protection for the ommatidia. Impairment in this process may result in characteristic 
phenotypes as a consequence, such as changes in the number of ommatidia and bristles. 
The eye-specific transgene GMR-Gal4 is used to investigate such phenotypic changes in 
the compound eye of D. melanogaster. Inhibition of Ref(2)P in the developing Drosophila 
eye results in a reduction in ommatidia number (Figure 4.7a) and interommatidial bristle 
number (Figure 4.7b) when compared to the control (UAS-lacZ).  
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Figure 4.1: Altered expression of Ref(2)P directed through the arm-Gal4 transgene 
affects lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using 
the log-rank test with Bonferroni correction. Error bars represent standard error of the 
mean. Genotypes are as follows: arm-Gal4;UAS-lacZ (n=284), arm-Gal4;UAS-Ref(2)P-
RNAiHMS00551 (n=240), arm-Gal4;UAS-Ref(2)P-RNAiHMS00938 (n=286). 
 
 
Figure 4.2: Altered expression of Ref(2)P directed through the elav-Gal4 transgene 
affects lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using 
the log-rank test with Bonferroni correction. Error bars represent standard error of the 
mean. Genotypes are as follows: elav-Gal4;UAS-lacZ (n=298), elav-Gal4;UAS-Ref(2)P-
















Figure 4.3: Altered expression of Ref(2)P directed through the D42-Gal4 transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered Ref(2)P expression in the motor neurons. Longevity is depicted 
by percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
D42-Gal4;UAS-lacZ (n=273), D42-Gal4;UAS-Ref(2)P-RNAiHMS00551 (n=252), D42-
Gal4;UAS-Ref(2)P-RNAiHMS00938 (n=303). B: Locomotor assay of D. melanogaster males 
displaying altered Ref(2)P expression in the motor neurons. Climbing ability was 
































Figure 4.4: Altered expression of Ref(2)P through the TH-Gal4 transgene affects 
longevity and climbing ability. A: Longevity assay of Drosophila melanogaster males 
displaying altered Ref(2)P expression in the dopaminergic neurons. Longevity is depicted 
by percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: TH-
Gal4;UAS-lacZ (n=291), TH-Gal4;UAS-Ref(2)P-RNAiHMS00551 (n=263), TH-Gal4;UAS-
Ref(2)P-RNAiHMS00938 (n=278). B: Locomotor assay of D. melanogaster males displaying 
altered Ref(2)P expression in the dopaminergic neurons. Climbing ability was determined 


















Figure 4.5: Altered expression of Ref(2)P directed through the ddc-Gal4HL4.3D transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered Ref(2)P expression in the motor neurons. Longevity is depicted 
by percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
ddc-Gal4HL4.3D;UAS-lacZ (n=293), ddc-Gal4HL4.3D;UAS-Ref(2)P-RNAiHMS00551 (n=241), 
ddc-Gal4HL4.3D;UAS-Ref(2)P-RNAiHMS00938 (n=249). B: Locomotor assay of D. 
melanogaster males displaying altered Ref(2)P expression in the motor neurons. 
Climbing ability was determined by a nonlinear curve fit (CI=95%). Error bars indicate 




Figure 4.6: Altered expression of Ref(2)P directed through the ddc-Gal4HL4.36 transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered Ref(2)P expression in the motor neurons. Longevity is depicted 
by percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
ddc-Gal4HL4.36;UAS-lacZ (n=284), ddc-Gal4HL4.36;UAS-Ref(2)P-RNAiHMS00938 (n=263). B: 
Locomotor assay of D. melanogaster males displaying altered Ref(2)P expression in the 
motor neurons. Climbing ability was determined by a nonlinear curve fit (CI=95%). Error 






















Figure 4.7: Directed Ref(2)P gene expression using eye-specific transgene GMR-Gal4 in 
Drosophila. Scanning electron micrographs of A: GMR-Gal4;UAS-lacZ, B: GMR-

















Figure 4.8: Biometric analysis of Drosophila compound eye under direct eye expression 
of Ref(2)P though the GMR-Gal4 transgene. Inhibition of Ref(2)P causes significant 
















 At the very least, the progression and pathogenesis of many neurodegenerative 
diseases are influenced by an impairment of cellular quality control, through conserved 
processes such as autophagy and the ubiquitin-proteasome system (UPS). As human 
p62/SQSTM1 encoded product is intimately involved in the autophagy process, with 
mutations known to be linked to neurodegenerative diseases (Bartolome et al., 2017; 
Narendra et al., 2010; Yamanda et al., 2019), investigation of this candidate gene may be 
quite informative. Altered expression of the Drosophila homologue, Ref(2)P has shown to 
affect median lifespan of the organism, locomotor function and neuronal development. 
Critical class flies, that express an inhibitory Ref(2)P transgene, exhibit a significant 
increase in aspects of longevity while displaying a significant reduction in motor function 
over time. Critical class males that cause inhibition of Ref(2)P in the developing 
compound eye displayed a significant reduction in ommatidia and bristle numbers. Such 
characteristic phenotypes are often due to an impairment in the development of the 
largely neuronally comprised Drosophila eye, and thus may suggest an impact on 
neurodevelopment. Unfortunately, a line that could readily lead to the overexpression 
of Ref(2)P was not readily available.  
 
Inhibition of Ref(2)P expression through the motor neuron-specific transgene  
D42-Gal4 has shown a significant increase in median lifespan while greatly reducing 
climbing ability throughout time. The increase in lifespan accompanied by a sharp 
decrease in motor function over time may be interpreted as trade-off, where the slight 
increase in longevity is a type of compensation for a severe decline in motor skills. This 
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significant reduction in motor ability and increase in lifespan when Ref(2)P expression is 
altered corresponds with the characteristic loss of motor neurons associated with ALS, 
making the inhibition of Ref(2)P in the motor neuron an imperfect model of 
neurodegenerative disease. Similarly, expression of Ref(2)P inhibition though the 
direction of the dopaminergic neuron-specific transgene TH-Gal4 has shown a 
significant, but minimal increase in median lifespan with a severe decline in climbing 
ability. Similar to the inhibition of Ref(2)P in the motor neurons, this increase in lifespan 
accompanied by a sharp decrease in motor function over time seen when Ref(2)P is 
inhibited in the dopaminergic neurons may also be interpreted as a type of compensation 
for a severe decline in motor skills. This significant reduction in motor ability and 
minimal increase in lifespan seen when Ref(2)P expression is altered, corresponds with 
the characteristic loss of dopaminergic neurons associated with Parkinson Disease, 
making the inhibition of  Ref(2)P in the motor neuron an promising model of 
neurodegenerative disease. 
 
The inhibition of Ref(2)P expression through the activities of the neuron-specific 
transgene ddc-Gal4HL4.3D significantly increased median lifespan, while displaying a 
severe decrease in climbing ability. Expressing Ref(2)P inhibition via UAS-Ref(2)P-
RNAiHMS00938 through the neuron-specific transgene ddc-Gal4HL4.36 has shown a 
significant increase in longevity, while significantly reducing climbing ability. This 
significant reduction in motor ability and increase in lifespan seen when Ref(2)P  
expression is altered may explained as compensational relationship, and seen as an 
imperfect model of neurodegenerative disease. Furthermore, the significant increase in 
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lifespan across all transgenes when Ref(2)P is inhibited suggests that it plays a substantial 
role in cell survival and death. As human p62/SQSTM1 has critical functions throughout 
the cell, specifically in autophagy and mitophagy, impairment and dysfunction of 
p62/SQSTM1 can be detrimental, with the loss-of-function of p62/SQSTM1 leading to an 
increase in oxidative stress and mitochondria damage (Bitto et al., 2014). The importance 
of functional p62/SQSTM1 in mitochondrial dynamics is evident in Drosophila as 
impairment of Ref(2)P reveals mitochondrial dysfunction, resulting in a decline in motor 
function (Pimenta De Castro et al., 2013). As the p62/SQSTM1 gene is a crucial player in 
the development and progression of many neurodegenerative diseases, including ALS, 
FTD and PD, along with having multiple functions within various cell pathways, a further 
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Chapter 6 - Modelling Human Neurodegenerative Disease Through Alteration of 
VCP/TER94 in Drosophila melanogaster 
 
6.1 Introduction 
As neurodegenerative diseases are prevalent in society and influence the lives of 
many individuals, the molecular pathways and cellular processes that are involved in 
disease pathogenesis must be more fully understood. Many neurodegenerative diseases, 
such as ALS and PD, have a number of genes linked to their development and 
progression of these diseases. Aside from the well-characterized disease-causing genes, 
there are several genes linked to disease pathology. Valosin-containing protein (VCP), 
known as TER94 in Drosophila, is an ALS-related gene which encodes the enzyme 
Valosin-Containing Protein, an essential AAA+ ATPase. In the cell, VCP is ubiquitously 
expressed in the endoplasmic reticulum, mitochondria and nucleus, with diverse functions 
in processes such as mitophagy, autophagy, UPS (Guo et al., 2016; Ludtmann et al., 
2017; Nguyen, Thombre, & Wang, 2018), as well as in ER-associated protein degradation 
and DNA repair (Guo et al., 2016; Nguyen et al., 2018). During mitophagy, VCP is 
required for mitochondrial outer membrane protein turnover (Tanaka et al., 2010), and is 
a direct component in the PINK1/parkin-mediated process of mitophagy (Kim et al., 
2013; Tanaka et al., 2010). In autophagy, VCP is heavily involved in the initiation phase 
and in the maturation of autophagosomes (Ju et al., 2009). An absence of VCP has been 
known to disturb both the aggregation of misfolded proteins, referred to as an 
aggreosome, along with the degradation of proteins (Ju et al., 2009). The human 
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VCP gene has interactions with two biochemical markers of autophagy, LC3 and 
p62/SQSTM1 (Y. Wang et al., 2011; Yeo & Yu, 2016), where mouse models expressing 
mutant VCP demonstrated an accumulation of both LC3 and p62/SQSTM1 (Yeo & Yu, 
2016). The various functions and cellular processes which VCP is involved suggest that 
this may be an excellent candidate gene to study neurodegenerative disease. 
 
Not only is the VCP gene associated with ALS, it is associated with many other 
diseases. VCP is known to be connected to early on-set Paget disease, FTD (Ludtmann et 
al., 2017; Mori et al., 2013), and more recently in PD (Mori et al., 2013). Through whole-
exome sequencing, mutations in the VCP gene have been linked to patients with familial 
ALS (Johnson et al., 2011), with mutations in VCP accounting for approximately 1 to 2% 
of familial ALS cases, demonstrating that VCP mutations can result in impaired 
autophagy (Nguyen et al., 2018). Dominant pathogenic mutations of VCP, result in 
changes within the N-domain or within the ATPase domains, that severely reduce 
mitochondrial function. (T. Wang et al., 2016). Similar to human VCP, the protein 
product of TER94 has associations with various select proteins in Drosophila, such 
as Cabeza (Cas), the Drosophila orthologue of the significant ALS gene FUS, where it 
functions as a modulator of motor neuron degeneration (Azuma et al., 2014). Consistent 
with VCP in humans, Drosophila TER94 regulates the Notch signalling pathway, which is 
critical in tissue development and homeostasis. Impairment of Notch signaling has been 
known to lead to various diseases, particularly neurodegenerative diseases (Li, Liu, & 
Zhang, 2019). Furthermore, TER94 interacts with Drosophila clueless (clu) through 
PINK1/Parkin-dependent mitophagy, where clu functions with VCP and parkin to 
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degrade and promote the clearance of dysfunctional mitochondria (T. Wang et al., 2016). 
As VCP has strong roles in the autophagy processes, particularly in the initiation stages, 
impairment in this gene along with its protein products, can have detrimental impacts on 
such pathways. Although previous work has been conducted on the role of VCP in 
degeneration, much is still unclear. The mechanisms by which mutations in VCP 
contribute to disease progression is an area of research that must be further investigated.   
 
The VCP gene has been highly conserved throughout evolutionary history. A 
comparison of human and D. melanogaster VCP proteins reveals six highly conserved 
domains: 1) the CDC48 N-terminal sub-domain; 2) the CDC48 domain 2; 3) the AAA+ 
ATPase domain; 4) the ATPase AAA type core domain; 5) the AAA ATPase AAA+ lid 
domain; and 6) the Vps4 oligomerization C-terminal domain. The degree of evolutionary 
conservation suggests a highly conserved function for the product of the VCP gene. Thus 
exploration of the effects of altered VCP expression in D. melanogaster promises to 
provide insights into the pathology of ALS in humans. In this study, overexpression and 
inhibition of VCP in D. melanogaster are used to mimic human conditions, examining the 








6.2 Materials and Methods  
 
6.2.1 Drosophila melanogaster stocks and culture  
 
All Drosophila stocks were obtained from the Bloomington Drosophila Stock 
Center at Indiana University (IN, USA). See Table 4.1 for list of genotypes used. See 
Chapter 2, section 2.1 for detail of D. melanogaster stocks and culture. 
 
6.2.2 Longevity Assay 
The survival of D. melanogaster was analyzed to examine the median lifespan of 
experimental flies in comparison to control flies. See Chapter 2, section 2.2 for full 
longevity assay methods.   
 
6.2.3 Locomotive Assay 
 The motor function of D. melanogaster was analyzed to examine the locomotor 
function over time of experimental flies in comparison to control flies. See Chapter 2, 
section 2.3 for full locomotive assay methods.   
 
6.2.4 Scanning Electron Microscopy of the Drosophila eye 
Eye analysis of D. melanogaster was used to determine the effects of gene 





Table 4.1: Genotypes and location of expression patterns used in the analysis of altered 
expression of TER94.   





Control Lines    
UAS-lacZ --- 2 Brand et al, 1993 
Driver Lines    
GMR-Gal4 Eye 2 Freeman, 1996 
arm-Gal4 Ubiquitous  2 Sanson et al., 
1996 




3 Inamdar et al., 
2014 
ddc-Gal4HL4.3D Dopaminergic and 
serotonergic neuron 
2 Li et al., 2000 
ddc-Gal4HL4.36 Dopaminergic and 
serotonergic neuron 
3 Li et al., 2000 
D42-Gal4 Motor neuron 3 Parkes et al., 1998 
Responder Lines    
UAS-TER94EY03486 --- 2 Bellen et al., 2004 
UAS-TER94-RNAiGS00593 --- 2 Perkins et al., 
2015 
UAS-TER94-RNAi GL00448 --- 3 Perkins et al., 
2015 
UAS-TER94-RNAi JF03402 --- 3 Perkins et al., 
2015 









6.3 Results  
6.3.1 Overexpression of TER94 influences median lifespan and climbing ability 
dependent on the expression pattern of the transgene  
 An investigation of the extent that the overexpression of TER94 influences the 
lifespan and climbing ability of D. melanogaster have shown that overexpression alters 
median lifespan and climbing depending on the expression of the transgene. When 
expressed through both the ubiquitous transgene arm-Gal4 (Figure 5.1) and the pan-
neuronal transgene elav-Gal4 (Figure 5.2) overexpression of TER94 significantly 
increases median lifespan when compared to the control (UAS-lacZ). When TER94 is 
overexpressed through the motor neuron-specific transgene, D42-Gal4, median lifespan 
significantly increased (Figure 5.3a), while climbing ability was reduced over time 
(Figure 5.3b) when compared to the control (UAS-lacZ). When TER94 is overexpressed 
through the dopaminergic neuron-specific transgene TH-Gal4, median lifespan was 
significantly reduced (Figure 5.4a), while climbing ability over time was not greatly 
changed (Figure 5.4b) when compared to the control (UAS-lacZ). When TER94 is 
overexpressed through the neuron-specific transgene, ddc-Gal4HL4.3D, median lifespan 
(Figure 5.5a) and climbing ability over time (Figure 5.5b) were significantly reduced 
when compared to the control (UAS-lacZ). 
 
6.3.2 Inhibition of TER94 decreases climbing ability but median lifespan is 
influenced dependent on the expression of the transgene 
An investigation of the inhibition of TER94 found that the lifespan and climbing 
ability of D. melanogaster was shown to be differentially altered. Four TER94 inhibition 
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lines were selected to investigate the consequences of each on the fly. When expressed 
through the activity of arm-Gal4 (Figure 5.1) and elav-Gal4 (Figure 5.2), TER94 
inhibition via UAS-TER94-RNAiGS00593 significantly increased median lifespan when 
compared to the control (UAS-lacZ). When expressed through arm-Gal4 and elav-Gal4, 
TER94 inhibition through both, UAS-TER94-RNAiHMS00656 and UAS-TER94-RNAiGL00448, 
significantly decreased median lifespan. Inhibition of TER94 through UAS-TER94-
RNAiJF03402 resulted in no critical class male progeny. When TER94 was inhibited via 
UAS-TER94-RNAiGS00593 through the motor neuron-specific transgene D42-Gal4, median 
lifespan was not significantly altered (Figure 5.3a), however climbing ability over time 
was reduced (Figure 5.3b) when compared to the control (UAS-lacZ). When TER94 was 
inhibited via both UAS-TER94-RNAiHMS00656 and UAS-TER94-RNAiJF03402 through D42-
Gal4 median lifespan was significantly increased, while TER94 inhibition through UAS-
TER94-RNAiGL00448 significantly reduced lifespan. Climbing ability was significantly 
reduced in these TER94 inhibition lines (Figure 5.3b) when compared to the control 
(UAS-lacZ). When TER94 was inhibited via UAS-TER94-RNAiGS00593 through the 
dopaminergic neuron-specific transgene TH-Gal4, median lifespan was not altered, while 
significantly reducing climbing ability. Inhibition of TER94 via UAS-TER94-
RNAiHMS00656 and UAS-TER94-RNAiGL00448 through TH-Gal4 significantly reduced 
median lifespan (Figure 5.4a) and climbing ability over time (Figure 5.4b) when 
compared to the control (UAS-lacZ). Inhibition of TER94 through UAS-TER94-
RNAiJF03402 did not provide critical class male progeny when expressed through TH-Gal4. 
When TER94 was inhibited via UAS-TER94-RNAiGS00593 and UAS-TER94-RNAiHMS00656 
through the neuron-specific transgene ddc-Gal4HL4.3D, median lifespan was significantly 
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increased (Figure 5.5a) while climbing ability was significantly reduced over time (Figure 
5.5b) when compared to the control (UAS-lacZ). When TER94 was inhibited via UAS-
TER94-RNAiGL00448 through ddc-Gal4HL4.3D lifespan was not influenced (Figure 5.5a), 
however climbing ability was reduced (Figure 5.5b). The inhibition of TER94 through 
UAS-TER94-RNAiJF03402 did not provide any critical class male progeny when expressed 
through ddc-Gal4HL4.3D. Lastly, TER94 inhibition via UAS-TER94-RNAiHMS00656 and UAS-
TER94-RNAiGL00448 through the neuron-specific transgene ddc-Gal4HL4.36, significantly 
increased median lifespan (Figure 5.6a) while climbing ability was significantly reduced 
over time (Figure 5.6b). Interestingly, when TER94 was inhibited via UAS-TER94-
RNAiJF03402 through ddc-Gal4HL4.36, critical class male progeny were viable. However, 
median lifespan (Figure 5.6a) and climbing ability over time (Figure 5.6b) were 
significantly reduced when compared to the control (UAS-lacZ). 
 
6.3.3 Overexpression and inhibition of TER94 decrease ommatidia and bristle 
number 
The developmental pattern of the Drosophila compound eye is a highly regulated 
and specific event with each eye being comprised of approximately 800 ommatidia under 
healthy development. Impairment in this process may result in characteristic phenotypes 
as a consequence, such as changes in the number of ommatidia and bristles. To 
investigate such phenotypic changes in D. melanogaster, the eye-specific transgene 
GMR-Gal4 was used. Altered TER94 expression underwent experimentation to 
investigate potential neurodevelopmental defects. Overexpression of TER94 shown a 
significant decrease in ommatidia number (Figure 5.8a) and interommatidial bristle 
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number (Figure 5.8b). While all TER94 inhibitory transgenes resulted in a significant 
decrease in bristle number when compared to the control (UAS-lacZ). Except for the 
TER94 inhibition transgene UAS-TER94-RNAiGL00448, all other loss-of-function genotypes 
result in a significant decrease in ommatidia number when compared to the control UAS-















Figure 5.1: Altered expression of TER94 directed through the arm-Gal4 transgene affects 
lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using the log-
rank test with Bonferroni correction. Error bars represent standard error of the mean. 
Genotypes are as follows: arm-Gal4;UAS-lacZ (n=284), arm-Gal4;UAS-TER94-
RNAiGL00448 (n=328), arm-Gal4;UAS-TER94-RNAiHMS00656 (n=92), arm-Gal4;UAS-TER94-
RNAiGS00593 (n=304), arm-Gal4;UAS-TER94EY03486 (n=212). 
Figure 5.2: Altered expression of TER94 directed through the elav-Gal4 transgene affects 
lifespan. Longevity is depicted by percent survival. Significance is P <0.05 using the log-
rank test with Bonferroni correction. Error bars represent standard error of the mean. 
Genotypes are as follows: elav-Gal4;UAS-lacZ (n=298), elav-Gal4;UAS-TER94-
RNAiGL00448 (n=305), elav-Gal4;UAS-TER94-RNAiHMS00656 (n=384), elav-Gal4;UAS-









Figure 5.3: Altered expression of TER94 directed through the D42-Gal4 transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered TER94 expression in the motor neurons. Longevity is depicted 
by percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
D42-Gal4;UAS-lacZ (n=273), D42-Gal4;UAS-TER94-RNAiGL00448 (n=281), D42-
Gal4;UAS-TER94-RNAiHMS00656 (n=272), D42-Gal4;UAS-TER94-RNAiJF03402 (n=200), 
D42-Gal4;UAS-TER94-RNAiGS00593 (n=219), D42-Gal4;UAS-TER94EY03486 (n=220). B: 
Locomotor assay of D. melanogaster males displaying altered TER94 expression in the 
motor neurons. Climbing ability was determined by a nonlinear curve fit (CI=95%). Error 










Figure 5.4: Altered expression of TER94 directed through the TH-Gal4 transgene affects 
longevity and climbing ability. A: Longevity assay of Drosophila melanogaster males 
displaying altered TER94 expression in the dopaminergic neurons. Longevity is depicted 
by percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: TH-
Gal4;UAS-lacZ (n=291), TH-Gal4;UAS-TER94-RNAiGL00448 (n=285), TH-Gal4;UAS-
TER94-RNAiHMS00656 (n=268), TH-Gal4;UAS-TER94-RNAiGS00593 (n=166), TH-Gal4;UAS-
TER94EY03486 (n=193). B: Locomotor assay of D. melanogaster males displaying altered 
TER94 expression in the dopaminergic neurons. Climbing ability was determined by a 




Figure 5.5: Altered expression of TER94 directed through the ddc-Gal4HL4.3D transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered TER94 expression in the neurons. Longevity is depicted by 
percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
ddc-Gal4HL4.3D;UAS-lacZ (n=293), ddc-Gal4HL4.3D;UAS-TER94-RNAiGL00448 (n=213), ddc-
Gal4HL4.3D;UAS-TER94-RNAiHMS00656 (n=246), ddc-Gal4HL4.3D;UAS-TER94-RNAiGS00593 
(n=211), ddc-Gal4HL4.3D;UAS-TER94EY03486 (n=171). B: Locomotor assay of D. 
melanogaster males displaying altered TER94 expression in the neurons. Climbing ability 





Figure 5.6: Altered expression of TER94 directed through the ddc-Gal4HL4.36 transgene 
affects longevity and climbing ability. A: Longevity assay of Drosophila melanogaster 
males displaying altered TER94 expression in the neurons. Longevity is depicted by 
percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
ddc-Gal4HL4.36;UAS-lacZ (n=284), ddc-Gal4HL4.36;UAS-TER94-RNAiJF03042 (n=229), ddc-
Gal4HL4.36;UAS-TER94-RNAiHMS00656 (n=246), ddc-Gal4HL4.36;UAS-TER94-RNAiGL00448 
(n=213). B: Locomotor assay of D. melanogaster males displaying altered TER94 
expression in the neurons. Climbing ability was determined by a nonlinear curve fit 

























Figure 5.7: Directed TER94 gene expression using the eye-specific transgene GMR-Gal4 
in Drosophila. Scanning electron micrographs of A: GMR-Gal4;UAS-lacZ, B: GMR-
Gal4;UAS-TER94EY03486, C: GMR-Gal4;UAS-TER94-RNAiJF03402, D: GMR-Gal4;UAS-






Figure 5.8: Biometric analysis of Drosophila compound eye under direct eye expression 
of TER94 though the GMR-Gal4 transgene. Overexpression of TER94 causes significant 
decrease in (A) ommatidia number. Both overexpression and inhibition of TER94 cause a 














In order to gain a fuller knowledge on the pathogenies of many neurodegenerative 
diseases, it is essential to examine not only the effects of major disease-causing genes, but 
the effects of less prominent disease-causing genes. Altered expression of TER94 
influenced Drosophila longevity, locomotor function and neuronal development, 
dependent upon the investigated pattern of expression. When TER94 was overexpressed 
through the ubiquitous transgene arm-Gal4, and the pan-neuronal transgene elav-Gal4, 
critical class males displayed a significant increase in median lifespan. Overexpression 
of TER94 though the motor neuron-specific transgene D42-Gal4 resulted in a slight 
increase in median lifespan. Whereas the overexpression of TER94 through the 
dopaminergic neuron-specific transgene TH-Gal4 and through the neuron-specific 
transgene ddc-Gal4HL4.3D decreased median lifespan. Overexpression of TER94 reduced 
climbing ability when expressed through D42-Gal4 and ddc-Gal4HL4.3D. The slight 
increase in median lifespan accompanied by the decline in motor skills over time when 
TER94 is overexpressed through the motor neuron-specific transgene D42-Gal4 seems to 
generate an imperfect model of neurodegenerative disease. As ALS is a motor neuron 
disease characterized by the loss of motor neurons, a decline in both longevity and motor 
function would appear to mimic the suggested pathology of ALS. However, the minimal 
increase in lifespan seen when TER94 is overexpressed in the motor neuron may suggest 
a delicate balance between longevity and motor function, where the slight increase in 
longevity is a reaction to the severe decline in motor skills. Critical class males 
overexpressing TER94 in the developing compound eye displayed a significant reduction 
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in ommatidia and bristle numbers. Such characteristic phenotypes are often due to an 
impairment in the development of the Drosophila eye, and thus may suggest a substantial 
role in neurodevelopment. 
 
Critical class males expressing transgenes that lead to the inhibition of TER94  
provided many inconclusive results. Expression of TER94 inhibition through UAS-
TER94-RNAiGS00593 displayed a significant increase in lifespan through the ubiquitous 
transgene arm-Gal4 and the neuron-specific transgene ddc-Gal4HL4.3D. While when 
expressed through the pan-neuronal transgene elav-Gal4, the motor neuron-specific 
transgene D42-Gal4, and the dopaminergic neuron-specific transgene TH-Gal4, lifespan 
was not changed. Inhibition of TER94 through expression of UAS-TER94-RNAiHMS00656 
and UAS-TER94-RNAiGL00448 produced varied results. When expressed through the 
transgenes arm-Gal4, elav-Gal4, and TH-Gal4, both TER94 inhibitory transgenes reduced 
median lifespan. While when expressed through ddc-Gal4HL4.36, both TER94 inhibitory 
transgenes increased median lifespan. Inhibition of TER94 via UAS-TER94-RNAiGL00448 
through D42-Gal4 and ddc-Gal4HL4.3D displayed a reduction in median lifespan, while 
TER94 inhibition through UAS-TER94-RNAiHMS00656 displayed a significant increase in 
median lifespan through these transgenes. Climbing ability was significantly reduced in 
all cases of TER94 inhibition across all transgenes investigated. From the varied results of 
this experiment several successful models of human neurodegeneration can be found. The 
reduction in lifespan and motor ability seen when TER94 is inhibited through TH-Gal4 
corresponds with the characteristic loss of dopaminergic neurons associated with PD—
making the inhibition of TER94 in the dopaminergic neurons a promising model of 
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neurodegenerative disease. While the reduction in median lifespan and motor function 
seen when TER94 is inhibited through D42-Gal4 corresponds with the characteristic loss 
of motor neurons associated with ALS – making the inhibition of TER94 in the motor 
neurons a promising model of neurodegenerative disease. 
 
Interestingly, TER94 inhibition through UAS-TER94-RNAiJF03402 provided critical 
class males when expressed through the transgenes D42-Gal4 and ddc-Gal4HL4.36 but not 
when expressed through other transgenes investigated. When expressed through D42-
Gal4, this TER94 inhibitory transgene produced an increase in median lifespan, while the 
climbing ability over time was reduced in a significant way. When expressed through 
 ddc-Gal4HL4.36, both median lifespan and climbing ability over the reduced life of the 
critical class flies were significantly reduced. As this particular TER94-RNAi transgene 
was not viable when expressed under the control of other Gal4 transgenes, and therefore, 
in other subsets of tissues, this may suggest that TER94 has a significant role in governing 
cell survival and viability in some tissues. As the human VCP protein is known to 
function in many cellular processes including autophagy, mitophagy and UPS (Guo et al., 
2016; Ludtmann et al., 2017; Nguyen, Thombre, & Wang, 2018), it is difficult to interpret 
the results of this study. Furthermore, as the VCP gene is a crucial component in various 
diseases, such as ALS and PD (Mori et al., 2013), a further investigation into the exact 
mechanisms of TER94 is required to understand its role fully. However, it can be said 
that TER94 is a strong participant in the development of some neurodegenerative 
diseases, such as ALS and PD.  
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Chapter 7 – Investigation of The Consequences of Combined Altered ALS And PD 
Gene Expression Activities in Drosophila melanogaster 
 
7.1 Introduction 
The neurodegenerative diseases Amyotrophic Lateral Sclerosis and Parkinson 
Disease are two movement disorders with substantial defects in proteostasis (Bosco, 
LaVoie, Petsko, & Ringe, 2011). Similarities between ALS and PD include the 
histopathological hallmarks of each disease, which typically are Lewy bodies in PD and 
Bunina bodies in ALS (Bosco et al., 2011; Yang & Choi, 2013), along with that current 
estimation that approximately 10% of cases have a known familial basis, with the 
majority thought to be sporadic in origin (Bosco et al., 2011). Other commonalities shared 
between ALS and PD are found within the cellular processes and pathways which govern 
disease progression, such as mitophagy. Specifically, it is the PINK1-parkin mitophagy 
pathway that is known to interact to at least some extent with major and minor ALS-
related genes. The major PD protein alpha-synuclein is known to have connections to 
multiple ALS-associated genes. Through further investigation of these potential 
connections, it may reveal links and gain a better understanding of the two diseases based 
on the cellular processes and pathways that contribute to disease progression.   
 
With regards to the major ALS gene TARDBP, its protein product, TDP-43 is 
reported to target long intron-containing pre-mRNA of parkin in humans (Sun et al., 
2018). Spinal cord samples taken from the autopsies of patients diagnosed with the 
sporadic form of ALS have shown that neurons containing TDP-43 protein inclusions 
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display reduced levels of the parkin protein (Sun et al., 2018). Studies have demonstrated 
impaired regulation of both PINK1 and parkin by the loss-of-function of TDP-43, to 
suggest that this mis-regulation may result in TDP-43-dependent proteinopathy (Lagier-
Tourenne et al., 2012; Sun et al., 2018). Specifically, the overexpression of TDP-43 in 
Drosophila has been shown to result in a decrease of parkin levels, which alters the 
turnover of PINK1 to cause an increase of the fraction of PINK1 protein that has had the 
amino terminal mitochondrial-localization peptide cleaved away in the cytosol (Sun et al., 
2018). The TDP-43 protein interacts with the alpha-synuclein protein, as they are known 
to coexist within Lewy bodies. The overexpression of TDP-43 in mice results in a 
moderate loss of cortical neurons (Tian et al., 2011), however, the combination of TDP-
43 overexpression and the presence of mutant forms of alpha-synuclein can lead to 
dopaminergic neurodegeneration. The loss of dopaminergic neurons from this 
combination is more severe than the consequences of increased expression of TDP-43, to 
suggest that these two proteins can play a cooperative role in neurodegeneration (Tian et 
al., 2011). The connections and roles that abnormal TDP-43, PINK1, parkin and alpha-
synuclein have on the cell may be indicators of a causal link between aspects of ALS and 
of PD.               
    
The ALS gene TBK1 is known to interact with PINK1-parkin pathway as this 
mechanism promotes TBK1 activation (Heo, Ordureau, Paulo, Rinehart, & Harper, 2015). 
Once TBK1 is activated, it then promotes the phosphorylation of its autophagy adaptors, 
p62/SQSTM1, OPTN and NDP52, which associate with autophagy ATG8 proteins 
through an LC3 interacting region motif (Heo et al., 2015). Among other proteins, 
 107 
p62/SQSTM1 is recruited to the mitochondria by parkin and participates in the 
aggregation of damaged mitochondria. However, it has been suggested that p62/SQSTM1 
may only have a role in the progression of aggregation and not in the process of 
mitophagy directly (Bitto et al., 2014; Narendra, Kane, Hauser, Fearnley, & Youle, 2010). 
Although this may be the case, p62/SQSTM1 is an excellent candidate gene to study due 
to an involvement in cellular homeostasis.  
 
Not only does the TBK1 gene interact with the PINK1-parkin pathway, its protein 
product interacts with the alpha-synuclein protein, where it has been demonstrated 
that alpha-synuclein fibrils in microglial cells have roles in the induction of autophagy by 
recruiting both TBK1 and OPTN to damaged sites in the microglial cell (Bussi et al., 
2018). The genetic interaction that TBK1 and OPTN have is of great interest to study, as 
to date, there is no obvious Drosophila homologue of the OPTN gene, and such 
experiments have to be delayed until, and if, a gene with similar duties is identified in 
Drosophila. Despite this, there are functional homologues of another major autophagy 
adaptor, p62/SQSTM1 which can be explored. Regarding known connections between 
p62/SQSTM1 and alpha-synuclein, it is known that alpha-synuclein protein inclusions 
can act as ideal targets for p62-dependent autophagy and that a p62/SQSTM1-deficiency 
enhances alpha-synuclein pathology (Tanji et al., 2015; Watanabe et al., 2012). As both 
TBK1 and p62/SQSTM1 appear to be highly influenced by PD gene activities, it would 
be beneficial to explore the extents of these connections.  
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The interactions that the VCP gene product has with the PINK1-parkin pathway 
may provide a great deal of insight, as this cooperation seems to function to directly 
identify damaged mitochondria for degradation (Ashrafi, Schlehe, LaVoie, & Schwarz, 
2014; Kim et al., 2013; Tanaka et al., 2010). Studies have been conducted on wild-
type VCP and its interactions with this pathway, and with VCP mutants, which 
demonstrated that loss of VCP functions impair the PINK1-Parkin pathway (Kim et al., 
2013). The Drosophila homologue of VCP, TER94 interacts with the clueless (clu) 
through PINK1/Parkin-dependent mitophagy, whereas clu functions with VCP and 
parkin to degrade and promote the clearance of dysfunctional mitochondria (T. Wang et 
al., 2016). As VCP has an active involvement with the process of PINK1-parkin 
mitophagy, and is a known ALS-related gene, it would be beneficial to study this ALS-
associated gene in terms of a potential relationship to PD. 
 
 
7.2 Materials and Methods  
 
7.2.1 Drosophila melanogaster stocks and culture  
 
All Drosophila stocks were obtained from the Bloomington Drosophila Stock 
Center at Indiana University (IN, USA), with the exception of the Gal4 lines w;ddc-
Gal4HL4.3D/CyO;UAS-parkin-RNAi/TM3 (ddc-Gal4HL4.3D;UAS-parkin-RNAi) and w;ddc-
Gal4HL4.36/Tm3 iso1;UAS-alpha-synuclein/CyO (ddc-Gal4HL4.36;UAS-alpha-synucelin) 
which were created in the Staveley Laboratory, Memorial University of Newfoundland 
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(St. John’s, Canada). See Table 5.1 for list of genotypes used. See, Chapter 2, section 2.1 
for detail of D. melanogaster stocks and culture. 
 
7.2.2 Longevity Assay 
The survival of D. melanogaster was analyzed to examine the median lifespan of 
experimental flies in comparison to control flies. See Chapter 2, section 2.2 for full 
longevity assay methods.   
 
7.2.3 Locomotive Assay 
 The motor function of D. melanogaster was analyzed to examine the locomotor 
function over time of experimental flies in comparison to control flies. See Chapter 2, 












Table 5.1: Genotypes and location of expression patterns used in the analysis of altered 
expression of ALS and PD gene activity.    





Control Lines    
UAS-lacZ --- 2 Brand et al, 1993 
Recombinant Driver Lines    
ddc-Gal4HL4.3D;UAS-parkin-
RNAi 




Neuron 3 Staveley, 
Unpublished 
Responder Lines    
UAS-TBPH-RNAiHMS01932 --- 2 Perkins et al., 
2015 
UAS-IK2EY09774 --- 2 Bellen et al., 2004 
UAS-Ref(2)P-RNAi HMS00938 --- 2 Perkins et al., 
2015 
UAS-TER94-RNAi GL00448 --- 3 Perkins et al., 
2015 
UAS-TER94-RNAi JF03402 --- 3 Perkins et al., 
2015 






















7.3 Results  
 
7.3.3 Inhibition of TBPH and the expression of alpha-synuclein significantly 
increases median lifespan but does not alter climbing ability 
 When expressed through the neuron-specific transgene ddc-Gal4HL4.36, located on 
insertion chromosome 3, TBPH inhibition through UAS-TBPH-RNAiHMS01932 did not show 
significant changes in median lifespan or climbing ability over time when compared to 
the control UAS-lacZ [see Chapter 3, section 3.3.1] and seen in [Figure 2.6]. However, the 
expression of alpha-synuclein, in addition to this, significantly reduced median lifespan 
(Figure 6.1a), while leaving climbing ability not significantly challenged (Figure 6.1b) 
 
7.3.4 Inhibition of TBPH and parkin significantly increases lifespan but does not 
alter lifetime climbing ability 
 When expressed through the neuron-specific transgene ddc-Gal4HL4.3D, located on 
insertion chromosome 2, TBPH inhibition via UAS-TBPH-RNAiHMS01932 showed a 
significant reduction in lifespan and climbing ability when compared to the control UAS-
lacZ [see Chapter 3, section 3.3.1; Figure 2.5]. The inhibition of parkin, in addition to the 
above, results in a significant reduction in median lifespan (Figure 6.2a) and climbing 
ability over time (Figure 6.2b). However, this reduction seems to be far greater than 





7.3.4 Inhibition of Ref(2)P and the expression of alpha-synuclein increases lifespan 
and reduces climbing ability 
When expressed through the neuron-specific transgene ddc-Gal4HL4. 36, located on 
insertion chromosome 3, Ref(2)P inhibition through UAS-Ref(2)P-RNAiHMS00938 
significantly increased lifespan, while significantly decreasing climbing ability when 
compared to the control UAS-lacZ [see Chapter 5, section 5.3.1; Figure 4.6]. The 
expression of alpha-synuclein, in addition to this, lead to a significant increase in median 
lifespan (Figure 6.3a), and decrease in climbing ability (Figure 6.3b).  
 
7.3.5 Inhibition of Ref(2)P and parkin increases lifespan and reduces climbing ability 
When expressed through the neuron-specific transgene ddc-Gal4HL4.3D, located on 
insertion chromosome 2, Ref(2)P inhibition via UAS-Ref(2)P-RNAiHMS00938 showed a 
significant increase in lifespan and decreased climbing ability when compared to the 
control UAS-lacZ [see Chapter 5, section 5.3.1; Figure 4.5]. The inhibition of parkin, in 
addition to this, also results in a significantly increased lifespan (Figure 6.2a), and 
reduced climbing ability (Figure 6.2b), however, this increase in lifespan is not as 
significant than without the inhibition of parkin. 
 
7.3.6 Inhibition of TER94 influences both lifespan and climbing ability when 
expressed with alpha-synuclein or parkin  
When expressed through the neuron-specific transgene ddc-Gal4HL4.36, located on 
insertion chromosome 3, TER94 inhibition via UAS-TER94-RNAiHMS00656 and UAS-
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TER94-RNAiGL00448 significantly increased median lifespan. In contrast, TER94 inhibition 
though UAS-TER94-RNAiJF03402 significantly decreased lifespan when compared to the 
control UAS-lacZ [see Chapter 6, section 6.3.2; Figure 5.6]. All inhibition lines 
significantly reduce climbing ability. The expression of alpha-synuclein, in addition to 
this, results in a significant decrease in median lifespan when TER94 inhibition was 
through UAS-TER94-RNAiJF03402 and UAS-TER94-RNAiGL00448. A significant increase in 
lifespan is seen with TER94 inhibition through UAS-TER94-RNAiHMS00656 (by ~28%) 
(Figure 6.5a). All inhibition lines result in a significant decrease in climbing ability 
(Figure 6.5b). 
 
7.3.7 Inhibition of TER94 influences both lifespan and climbing ability when 
expressed with alpha-synuclein or parkin  
When expressed through the neuron-specific transgene ddc-Gal4HL4.3D, located on 
insertion chromosome 2, TER94 inhibition via UAS-TER94-RNAiGL00448 did not 
significantly impact lifespan but significantly decreased climbing ability compared to the 
control UAS-lacZ  [see Chapter 6, section 6.3.2; Figure 5.5]. When parkin is inhibited, in 
addition to this, median lifespan was significantly reduced by (~30%) (Figure 6.6a), while 






Figure 6.1: Altered expression of TBPH and the expression of alpha-synuclein directed 
through the ddc-Gal4HL4.36 transgene does not affects longevity and climbing ability. A: 
Longevity assay of Drosophila melanogaster males displaying the expression of alpha-
synuclein and the altered TBPH expression in the neurons. Longevity is depicted by 
percent survival. Significance is P <0.05 using the log-rank test with Bonferroni 
correction. Error bars represent standard error of the mean. Genotypes are as follows: 
ddc-Gal4HL4.36;UAS-alpha-synuclein;UAS-lacZ (n=228), ddc-Gal4HL4.36;UAS-alpha-
synuclein;UAS-TBPH-RNAiHMS01932 (n=261). B: Locomotor assay of D. melanogaster 
males displaying the expression of alpha-synuclein and the altered TBPH expression in 
the neurons. Climbing ability was determined by a nonlinear curve fit (CI=95%). Error 




Figure 6.2 : Altered expression of TBPH and parkin directed through the ddc-Gal4HL4.3D 
transgene does not affects longevity and climbing ability. A: Longevity assay of 
Drosophila melanogaster males displaying altered TBPH and parkin expression in the 
neurons. Longevity is depicted by percent survival. Significance is P <0.05 using the log-
rank test with Bonferroni correction. Error bars represent standard error of the mean. 
Genotypes are as follows: ddc-Gal4HL4.3D;UAS-parkin-RNAi;UAS-lacZ (n=253), ddc-
Gal4HL4.3D;UAS-alpha-synuclein;UAS-TBPH-RNAiHMS01932 (n=253). B: Locomotor assay of 
D. melanogaster males altered TBPH and parkin expression in the neurons. Climbing 
ability was determined by a nonlinear curve fit (CI=95%). Error bars indicate standard 





Figure 6.3 : Altered expression of Ref(2)P and the expression of alpha-synuclein directed 
through the ddc-Gal4HL4.36 transgene affects longevity and climbing ability. A: Longevity 
assay of Drosophila melanogaster males displaying the expression of alpha-synuclein 
and the altered Ref(2)P expression in the neurons. Longevity is depicted by percent 
survival. Significance is P <0.05 using the log-rank test with Bonferroni correction. Error 
bars represent standard error of the mean. Genotypes are as follows: ddc-Gal4HL4.36;UAS-
alpha-synuclein;UAS-lacZ (n=228), ddc-Gal4HL4.36;UAS-alpha-synuclein;UAS-Ref(2)P-
RNAiHMS00938 (n=281). B: Locomotor assay of D. melanogaster males displaying the 
expression of alpha-synuclein and the altered Ref(2)P expression in the neurons. 
Climbing ability was determined by a nonlinear curve fit (CI=95%). Error bars indicate 





Figure 6.4: Altered expression of Ref(2)P and parkin directed through the ddc-Gal4HL4.3D 
transgene affects longevity and climbing ability. A: Longevity assay of Drosophila 
melanogaster males displaying altered Ref(2)P and parkin expression in the neurons. 
Longevity is depicted by percent survival. Significance is P <0.05 using the log-rank test 
with Bonferroni correction. Error bars represent standard error of the mean. Genotypes 
are as follows: ddc-Gal4HL4.3D;UAS-parkin-RNAi;UAS-lacZ (n=253), ddc-Gal4HL4.3D;UAS-
parkin-RNAi;UAS-Ref(2)P-RNAiHMS00938 (n=267). B: Locomotor assay of D. melanogaster 
males altered Ref(2)P and parkin expression in the neurons. Climbing ability was 





Figure 6.5: Altered expression of TER94 and the expression of alpha-synuclein directed 
through the ddc-Gal4HL4.36 transgene affects longevity and climbing ability. A: Longevity 
assay of Drosophila melanogaster males displaying the expression of alpha-synuclein 
and the altered TER94 expression in the neurons. Longevity is depicted by percent 
survival. Significance is P <0.05 using the log-rank test with Bonferroni correction. Error 
bars represent standard error of the mean. Genotypes are as follows: ddc-Gal4HL4.36;UAS-
alpha-synuclein;UAS-lacZ (n=228), ddc-Gal4HL4.36;UAS-alpha-synuclein;UAS-TER94-
RNAiJF03402 (n=275), ddc-Gal4HL4.36;UAS-alpha-synuclein;UAS-TER94-RNAiHMS00656 
(n=286), ddc-Gal4HL4.36;UAS-alpha-synuclein;UAS-TER94-RNAiGL00448 (n=242). B: 
Locomotor assay of D. melanogaster males displaying the expression of alpha-synuclein 
and the altered TER94 expression in the neurons. Climbing ability was determined by a 





Figure 6.6: Altered expression of TER94 and parkin directed through the ddc-Gal4HL4.3D 
transgene affects longevity and climbing ability. A: Longevity assay of Drosophila 
melanogaster males displaying altered TER94 and parkin expression in the neurons. 
Longevity is depicted by percent survival. Significance is P <0.05 using the log-rank test 
with Bonferroni correction. Error bars represent standard error of the mean. Genotypes 
are as follows: ddc-Gal4HL4.3D;UAS-parkin-RNAi;UAS-lacZ (n=253), ddc-Gal4HL4.3D;UAS-
parkin-RNAi;UAS-TER94-RNAiGL00448 (n=280). B: Locomotor assay of D. melanogaster 
males altered TER94 and parkin expression in the neurons. Climbing ability was 












 D. melanogaster was used as a model to examine the consequences of the altered 
combined of ALS-related and PD-related gene expression. To explore this interaction 
several longevity and locomotor function throughout lifespan experiments were 
conducted. When directed through the neuron-specific transgene ddc-Gal4HL4.36, 
inhibition of TBPH via the UAS-TBPH-RNAiHMS01932 transgene did not influence median 
lifespan or climbing ability [see Chapter 3, section 3.3.1]. However, when alpha-
synuclein is expressed in addition to the inhibition of TBPH, the median lifespan was 
significantly increased with no great changes in climbing ability. The large increase in 
lifespan that is obtained when alpha-synuclein is expressed in the ddc-Gal4-expressing 
neural tissues suggests that the interaction between TBPH and alpha-synuclein is 
important.  
 
Furthermore, the TDP-43 protein is known to interact with the parkin protein of 
the PINK1/parkin pathway. When expressed through the neuron-specific transgene ddc-
Gal4HL4.3D the inhibition of the Drosophila homologue, TBPH through UAS-TBPH-
RNAiHMS01932 reduced both lifespan and climbing ability [see Chapter 3, section 3.3.1]. 
When parkin was inhibited in addition to this, lifespan and climbing ability were also 
reduced. However, the reduction in lifespan, as well as climbing ability, displayed when 
both TBPH and parkin were inhibited was more severe than the inhibition of TBPH 
without altering parkin, to suggest that the interaction the two proteins share is essential 
to cell survival. As human TDP-43 is known to reduce parkin levels in the neuron and 
impair the regulation of both parkin and PINK1 (Sun et al., 2018), the results of this 
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experiment seem to support this finding, with the influence upon Drosophila being a 
reduction in lifespan and locomotor functions. The inhibition of TBPH and parkin in the 
neuron appears to mimic the suggested pathology of ALS and PD, making it a promising 
model of neurodegenerative disease. 
 
Human TBK1 and p62/SQSTM1 are two ALS-related genes that have their 
activation dependent upon the PINK1/parkin pathway. Gene interaction experiments were 
attempted between the overexpression of Drosophila IK2, the fly equivalent of TBK1, and 
the addition of alpha-synuclein through the neuron-specific transgene ddc-Gal4HL4.36. 
Experiments were attempted between the overexpression of IK2 and inhibition of parkin 
through the neuron-specific transgene ddc-Gal4HL4.3D; however critical class males were 
not obtained for either experiment, once again suggesting that IK2 has essential roles in 
viability. Gene interactions experiments between Drosophila Ref(2)P, the fly equivalent 
of p62/SQSTM1, with both alpha-synuclein and parkin were conducted to examine the 
impacts to the fly. When expressed through the neuron-specific transgene ddc-Gal4HL4.36, 
the inhibition of Ref(2)P through UAS-Ref(2)P-RNAiHMS00938 increased median lifespan, 
while decreased climbing ability [see Chapter 5, section 5.3.1]. When alpha-synuclein 
 was expressed in addition to this, median lifespan was increased, however climbing 
ability was not impacted. Despite this increase in lifespan displayed when alpha 
synuclein is expressed concurrently with the inhibition of Ref(2)P, this increase in very 
minimal. As a reduction in human p62/SQSTM1 is known to enhance the pathology 
of alpha-synuclein, this may support the small reduction in lifespan seen when alpha-
synuclein was expressed with a loss-of-function of Ref(2)P. 
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During PINK1-parkin-mediated mitophagy, the human protein p62/SQSTM1 is 
recruited by parkin to the mitochondria, where it acts to function in the aggregation of 
damaged mitochondria (Bitto et al., 2014; Narendra et al., 2010). Genetic interaction 
experiments were conducted to observe the consequences of the impairment of 
p62/SQSTM1 and parkin have upon the median lifespan and the locomotor function. 
When expressed through the neuron-specific transgene ddc-Gal4HL4.3D, inhibition of 
Drosophila Ref(2)P via UAS-Ref(2)P-RNAiHMS00938 increased lifespan but decreased 
climbing ability over the life of the flies [see Chapter 5, section 5.3.1]. The inhibition 
of parkin in combination with the loss of function of Ref(2)P, increased median lifespan, 
while climbing ability was reduced in a manner similar to the simple loss of Ref(2)P 
function. The results of gene interaction experiments between Ref(2)P and parkin genes 
suggest a strong connection; however, a further investigation must be done to understand 
their roles thoroughly.  
            
As the VCP protein directly functions to mark mitochondria for destruction and 
aid in the clearance, it appears to be a key component in the PINK1-parkin mitophagy 
pathway (Ashrafi, Schlehe, LaVoie, & Schwarz, 2014; Kim et al., 2013). Gene interaction 
experiments between Drosophila TER94, the fly equivalent of VCP, and altered PD gene 
activities has revealed complex results when TER94 is expressed through the neuron-
specific transgene ddc-Gal4HL4.36. Inhibition of TER94 through UAS-TER94-RNAiJF03402 
provided a significant decrease in both lifespan and climbing ability, while the inhibition 
of TER94 through the directed expression of UAS-TER94-RNAiHMS00656 and UAS-TER94-
RNAiGL00448 gave an increase in lifespan coupled with a significant lifetime reduction in 
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climbing ability [see Chapter 6, section 6.3.2]. When alpha-synuclein was expressed in 
addition to the loss of TER94 function, TER94 inhibition through UAS-TER94-
RNAiJF03402 continued to display a similar reduction in lifespan and climbing ability. In 
contrast, TER94 inhibition through UAS-TER94-RNAiGL0044 resulted in a significant 
decrease in lifespan. Interestingly, TER94 inhibition through UAS-TER94-RNAiHMS00656 
gave a significant increase in lifespan when alpha-synuclein was co-expressed. 
As TER94 inhibition through UAS-TER94-RNAiGL00448 alone resulted in an increased 
lifespan, but the addition of alpha-synuclein lead to a reduction in lifespan, this suggests 
that alpha-synuclein interacts with the TER94 protein to some extent. The inhibition of 
TER94 through UAS-TER94-RNAiHMS00656 increased lifespan; however, the addition 
of alpha-synuclein lead to an even greater increase in lifespan by approximately 28%. 
This major increase in longevity seen by the inhibition of TER94 and expression of alpha-
synuclein to suggest a strong connection between the two gene activities and a clear 
synergistic effect where the combined effects of TER94 inhibition and the expression 
of alpha-synuclein are greater than either alteration in isolation. 
 
Human VCP has been suggested to play critical roles in mitophagy as it has been 
demonstrated to be a component of the PINK1/parkin pathway. As both mutant and wild-
type VCP are known to have great influence upon aspects of the PINK1/parkin pathway 
(Kim et al., 2013), which may result in impairment of this pathways, genetic interactions 
between the Drosophila TER94 and parkin genes were conducted. When expressed 
through the neuron-specific transgene ddc-Gal4HL4.3D, the inhibition of TER94 through 
the directed expression of UAS-TER94-RNAiGL00448 did not alter median lifespan but did 
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reduce climbing ability over time [see Chapter 6, section 6.3.2]. The combined inhibition 
of both parkin and TER94 resulted in a major reduction in median lifespan by 
approximately 30% along with the reduction of climbing ability. The considerable 
reduction in longevity observed when parkin has been inhibited further suggests a 
significant functional connection between TER94 and parkin. This substantial decrease in 
lifespan and decline in motor function appears to mimic aspects of the pathology of ALS 
and PD, thus reinforcing the promise of this combination of altered gene expression as a 
model of neurodegenerative disease. However, further investigation into TER94 and 
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Chapter 8 – Summary 
8.1 Summary  
 The use of model organisms such as D. melanogaster provides a simple but 
powerful way to investigate the biological consequences of altered gene expression. As 
altered TBPH is a hallmark of degenerating neurons, specifically the motor neurons, the 
reduction in median lifespan and locomotor function observed in D. melanogaster when 
levels of TBPH activity were inhibited in the motor neurons is an attempt to mimic the 
related pathologies observed in ALS patients (Feiguin et al., 2009; Zhan, Hanson, Kim, 
Tare, & Tibbetts, 2013). Critical class flies that expressed the loss-of-function of TBPH in 
the motor neurons presented with a reduction in median lifespan and motor ability over 
time, to provide a model of the neurodegenerative disease [see Chapter 3, Figure 2.3].  
The investigation of interactions between TBPH and alpha-synuclein and with parkin 
 provided unremarkable results as the additional expression of alpha-synuclein nor the 
inhibition of parkin in combination with TBPH inhibition did not strongly influence D. 
melanogaster [see Chapter 7, Figure 6.1-6.2]. A more in-depth exploration into the 
cellular mechanisms by which TBPH expression is altered in a diseased state, eventually 
may lead to novel treatment options for ALS patients.   
 
           Investigating the consequences of altered IK2 expression gave either a lethal 
phenotype or lack of viability when IK2 was overexpressed, while IK2 inhibition was 
produced variable outcomes. Previously, it was known that IK2 plays a vital role in 
developing neurons, with functions in dendrite pruning and neuronal re-modelling (Lee, 
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Jan, & Jan, 2009; Lin et al., 2015). The reduction in lifespan and locomotor function 
produced in D. melanogaster when IK2 levels were increased in the motor neuron in an 
attempt to mimic the effects seen in ALS patients. The overexpression of IK2 in the motor 
neuron can provide an imperfect model of neurodegenerative disease [see Chapter 4, 
Figure 3.3]; however, the process by which IK2 expression is altered must be further 
investigated.  
 
The high level of conservation and similarity between human p62/SQSTM1 and 
Drosophila Ref(2)P allows investigation of the effects of altered Ref(2)P expression in 
Drosophila neurons is of particular interest (Devorkin & Gorski, 2014).The increase in 
median lifespan and reduction in motor ability displayed in D. melanogaster when 
Ref(2)P levels are inhibited in the neurons, motor neurons as well as dopaminergic 
neurons, can provide a range of models of neurodegenerative disease. However, the loss 
of Ref(2)P function led to an increase in median lifespan accompanied by a severe 
reduction in motor skills may be functioning as a type of compensation, where the slight 
increase in longevity is the consequence for a severe decline in motor skills [see Chapter 
5, Figures 4.3 to 4.5]. The role that Ref(2)P plays in autophagy is substantial, with protein 
levels as well as protein aggregates accumulate when autophagy is impaired (Bartlett et 
al., 2011; Devorkin & Gorski, 2014). The accretion of protein aggregates when the 
processes of autophagy are non-functional well may be thought of as a signature 
characteristic of a number of neurodegenerative diseases. 
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The investigation of potential synergies between Ref(2)P and alpha-synuclein did 
not produce striking results: the directed expression of alpha-synuclein in combination 
with the inhibition of Ref(2)P did not show a strong interactive relationship upon the 
phenotypes of median lifespan or health-span in D. melanogaster [see Chapter 7, Figure 
6.3]. However, the phenotypes observed in D. melanogaster when both Ref(2)P and 
parkin are inhibited through RNAi have shown that the inhibition of this combination of 
genes results in a significant increase in median lifespan with a notable reduction in 
lifetime motor function [see Chapter 7, Figure 6.4]. However, the increase in median 
lifespan obtained with the inhibition of Ref(2)P without alteration in parkin is more 
substantial than the inhibition of parkin without concurrent changes to Ref(2)P 
expression. Further investigation into the cellular mechanisms dependent upon 
Ref(2)P and parkin is required to better understand this biological connection. 
 
           Investigation of the consequences of altered TER94 expression provided a number 
of divergent results which were dependent upon both the Gal4 transgene used and the 
TER94 and TER94-RNAi transgenes selected. As TER94 has been demonstrated to 
process multiple roles in the cell, interact with various proteins and functioning in several 
cellular pathways, it is difficult to understand the extent of its influence through these 
experiments. The small increase in median lifespan and the sharp decline in locomotor 
function was observed in D. melanogaster when TER94 levels were increased in the D42-
Gal4-expressing motor neurons is an attempt to mimic the effects seen in ALS patients. 
Despite TER94 overexpression providing a slight increase in lifespan, this may be 
functioning as an indirect consequence, where the slight increase in longevity may be a 
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compensation mechanism for a severe decline in motor skills. The minimal increase in 
lifespan and a sharp decline in motor ability observed in D. melanogaster when  
TER94 was overexpressed in the motor neuron provides an imperfect model of 
neurodegenerative disease [see Chapter 6, Figure 5.3]. Moreover, the reduction in median 
lifespan and motor ability generated when TER94 expression is inhibited in the 
dopaminergic neurons corresponds with the characteristic loss of dopaminergic neurons 
associated with PD, to suggest strongly that the inhibition of TER94 in the dopaminergic 
neuron a promising model of neurodegenerative disease [see Chapter 6, Figure 5.4].  
 
The investigation of interactions between TER94 and alpha-synuclein resulted in a 
great increase in lifespan (~28%) and reduction in motor ability in D. melanogaster 
when TER94 levels were inhibited, and alpha-synuclein was co-expressed, to suggests the 
potential of a synergistic interaction between the two [see Chapter 7, Figure 6.5]. On the 
other hand, the major reduction in median lifespan (~30%) and motor ability observed 
when both TER94 and parkin levels were reduced is a promising model of 
neurodegenerative disease [see Chapter 7, Figure 6.6], as TER94 is thought to be a 
component of the PINK1/parkin mitophagy mechanisms, with an important function in 
the destruction and clearance of damaged mitochondria (Ashrafi et al., 2014; Kim et al., 
2013). A more in-depth understanding of TER94 functions in the cell is required to 
broaden our knowledge of ALS and PD pathogenesis.  
 
Neurodegenerative diseases have become very prevalent in the aging population 
of today, with a significant impact upon the lives of many individuals. Such diseases 
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greatly influence the lifespan, health and overall quality of life of those affected. By 
understanding the molecular pathways and cellular processes that are involved in disease 
pathogenesis, it may then be possible to create more advanced treatments, therapeutics to 
improve the longevity and health of these patients, and, eventually, a series of treatments 
to contribute to an eventual cure. The implication of the disease-related genes in this 
study may be of clinical significance, as altered gene expression affects longevity and 
motor function in Drosophila melanogaster. 
 
8.2 Future Directions 
 
 The work of this study lays down a solid foundation of the biological consequences 
that altered autophagic gene activity has on Drosophila melanogaster survival and motor 
function. However, despite this there is continued work that is still to come from this study. 
Future research should investigate other ALS-related genes, such as FUS, which is known 
to act in conjunction with TDP-43, as well as genes from the Atg protein family, such as 
LC3/Atg8. Other experiments could look into the role of diet in disease, as diet is known 
to have a huge influence in our health. Studies have suggested the role of a high glucose 
diet as a form of treatment for ALS as it has been observed to protect nerve cells from 
pathological protein aggregates, such as TDP-43 aggregates, that result in neuronal death 
(Manzo et al., 2019). Furthermore, experiments investigating the interactions of TER94 
with other genes involved in the mitophagy process such as Ref(2)P, clueless and parkin 
would be of great interest.  
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Appendix A – Supplemental Data for Chapter 1  
 
A1. Protein sequence alignment of Drosophila melanogaster TBPH and Homo sapiens 
TDP-43. Alignment performed in Clustral Omega.  
 
Drosophila      -MDFVQVSEEEGDEPIELPAEEDGTLLLSTLQAQFPGSCGLKYRNLDTKAVRGVRSNEGR 59 
Homo            MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI 60 
Mus             MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI 60 
                  ::::*:*:*.*****:*:*:***:****: *****:***:***  ::.:****  **  
 
Drosophila      LFPPSVESGWGEYAYFCVFPKENKRKSDDNLENSTAKTKRIETRLRCTDLIVLGLPWKTT 119 
Homo            LHAP--DAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRA--VQKTSDLIVLGLPWKTT 116 
Mus             LHAP--DAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRA--VQKTSDLIVLGLPWKTT 116 
                *. *  ::***: .*.  :**:**** *:.  .*:.*.**     : :************ 
 
Drosophila      EESLREYFETYGEVLMAQIKKDTKSGQSKGFGFVRFGSYDAQMRVLTNRHLIDGRWCEVK 179 
Homo            EQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCK 176 
Mus             EQDLKDYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCK 176 
                *:.*::**.*:*****.*:*** *:*:********* .*::*::*:::**:******: * 
 
Drosophila      VPNSKGMGHQ--VPCKVFVGRCTEDINSDDLREYFSKFGEVTDVFIPRPFRAFSFVTFLD 237 
Homo            LPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFAD 236 
Mus             LPNSKQSPDEPLRSRKVFVGRCTEDMTAEELQQFFCQYGEVVDVFIPKPFRAFAFVTFAD 236 
                :****   .:     **********:. ::*:::*.::*:* *****:*****:**** * 
 
Drosophila      PDVAQSLCGEDHIIKGVSVHVSNAAPKAEQNRNQQVQSYNYNSANSFGMHSY-------- 289 
Homo            DQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGG 296 
Mus             DKVAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGG 296 
                 .:******** ****:***:*** ** :.**: : ..   .. ..** :.          
 
Drosophila      ----HPQGNHMNPGRNGHHRGRQFSILDGSERGPQQC-QQLWWTEGAE------------ 332 
Homo            AGLGNNQGSNMGGG----MNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGN 352 
Mus             AGLGNNQGGNMGGG----MNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGN 352 
                    : **.:*. *     .   ***  .   . * . *. *   *               
 
Drosophila      ------------------------------------------------------------ 332 
Homo            NQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGW 412 
Mus             NQSQGSMQREPNQAFGSGNNSYSGSNSGAPLGWGSASNAGSGSGFNGGFGSSMDSKSSGW 412 
                                                                             
 
Drosophila      -- 332 
Homo            GM 414 
Mus             GM 414 
 
Highlighted are the TAR DNA binding protein 43, N-terminal domain (red), RNA 
recognition motif 1 (dark blue), RNA recognition motif 2 (orange text), Nuclear 
localization sequence (magenta) and Nuclear export signal (turquoise). “*” indicates 
amino acids that are identical in all sequences within the alignment, “:” indicates 
conserved substitutions, and “.” indicates semiconserved substitutions. Protein sequences 
for Homo sapiens (accession number NP_031401.1), Drosophila melanogaster (accession 
number NM_058051), and Mus musculus (accession number sp | Q921F2.1) were 










A2. Protein sequence alignment of Drosophila melanogaster IK2 and Homo sapiens 
TBK1. Alignment performed in Clustral Omega 
 
Drosophila      MSFLRGSVSYVWCTTSVLGKGATGSVFQGVNKITGESVAVKTFNPYSHMRPADVQMREFE 60 
Homo            ---MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMREFE 57 
Mus             ---MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLYAVKVFNNISFLRPVDVQMREFE 57 
                   ::.: .::*  :.:**:***..**:* :* **:  *:*.**  *.:**.******** 
 
Drosophila      ALKKVNHENIVKLLAIEEDQEGRGKVIVMELCTGGSLFNILDDPENSYGLPEHEFLLVLE 120 
Homo            VLKKLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLR 117 
Mus             VLKKLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLR 117 
                .***:**:*****:****:   * **::**:*  ***:.:*::*.*:***** ***:**. 
 
Drosophila      HLCAGMKHLRDNKLVHRDLKPGNIMKFISEDGQTIYKLTDFGAARELEDNQPFASLYGTE 180 
Homo            DVVGGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTE 177 
Mus             DVVGGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTE 177 
                .: .**:***:* :****:******:.*.****::**************:: *.****** 
 
Drosophila      EYLHPDLYERAVLRKSIQRSFTANVDLWSIGVTLYHVATGNLPFRPFGGR-KNRETMHQI 239 
Homo            EYLHPDMYERAVLRKDHQKKYGATVDLWSIGVTFYHAATGSLPFRPFEGPRRNKEVMYKI 237 
Mus             EYLHPDMYERAVLRKDHQKKYGATVDLWSVGVTFYHAATGSLPFRPFEGPRRNKEVMYKI 237 
                ******:********. *:.: *.*****:***:**.***.****** *  :*:*.*::* 
 
Drosophila      TTKKASGVISGTQLSENGPIEWSTTLPPHAHLSQGLKTLVTPLLAGLLEENREKTWSFDR 299 
Homo            ITGKPSGAISGVQKAENGPIDWSGDMPVSCSLSRGLQVLLTPVLANILEADQEKCWGFDQ 297 
Mus             ITGKPSGAISGVQKAENGPIDWSGDMPLSCSLSQGLQALLTPVLANILEADQEKCWGFDQ 297 
                 * * **.***.* :*****:**  :*  . **:**:.*:**:**.:** ::** *.**: 
 
Drosophila      FFHEVTLILRKRVIHVFFTNRTSSVEVFLEPDEQIDNFRERIFLQTEVPLEKQILLFNNE 359 
Homo            FFAETSDILHRMVIHVFSLQQMTAHKIYIHSYNTATIFHELVYKQTKIISSNQELIYEGR 357 
Mus             FFAETSDVLHRMVIHVFSLQHMTAHKIYIHSYNTAAVFHELVYKQTKIVSSNQELIYEGR 357 
                ** *.: :*:: *****  :: :: ::::.  :    *:* :: **::  .:* *:::.. 
 
Drosophila      HLEKKVTPRTIAKAFPATTTDQPIFLYSNDDNNVQLPQQLDLPKFPVFPPNVSVENDASL 419 
Homo            RL--VLEPGRLAQHFPKTTEENPIFVVSREPLNTI-GLIYEKISLPKVHPRYDLDGDASM 414 
Mus             RL--VLELGRLAQHFPKTTEENPIFVTSREQLNTV-GLRYEKISLPKIHPRYDLDGDASM 414 
                :*   :    :*: ** ** ::***: *.:  *.      :  .:* . *. .::.***: 
 
Drosophila      AKSACSVGHECKRRVDIFTSMDILIKKGVEHFIEMLVTTITLLLKKTES--------FDN 471 
Homo            AKAITGVVCYACRIASTLLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLDFCIRN 474 
Mus             AKAVTGVVCYACRTASTLLLYQELMRKGVRWLVELVKDDYNETVHKKTEVVITLDFCIRN 474 
                **:  .*   . * .. :   : *::**:. ::*::    .  ::*. .        : * 
 
Drosophila      LLSTVIDYADVVHSMARVTKGDQEIKTLLTALENVKSDFDGAADVISQMHKHFVIDDELN 531 
Homo            IEKTVKVYEKLMKINLE-AAELGEISDIHTKLLRLSSSQGTIETSLQDIDSRLSPGGSLA 533 
Mus             IEKTVKVYEKLMKVNLE-AAELGEISDIHTKLLRLSSSQGTIESSLQDISSRLSPGGLLA 533 
                : .**  * .:::   . :    **. : * * .:.*. .     :.:: .::  .. *  
 
Drosophila      DQWTSSMHGKKCPCKTRASAQAKYLVERLRDSWQHLLRDRATRTLTYNDEQFHALEKIKV 591 
Homo            DAWAHQEGT---HPKDRNVEKLQVLLNCMTEIYYQFKKDKAERRLAYNEEQIHKFDKQKL 590 
Mus             DTWAHQEGT---HPRDRNVEKLQVLLNCITEIYYQFKKDKAERRLAYNEEQIHKFDKQKL 590 
                * *: .        : *   : : *:: : : : :: :*:* * *:**:**:* ::* *: 
 
Drosophila      DHNGKRIKALLLDNVNPTVAQIAECLADWYKLAQTVYLKTQILE--KDVRDCERKLN--- 646 
Homo            YYHATKAMTHFTDECVKKYEAFLNKSEEWIRKMLH--LRKQLLSLTNQCFDIEEEVSKYQ 648 
Mus             YYHATKAMSHFSEECVRKYEAFKDKSEEWMRKMLH--LRKQLLSLTNQCFDIEEEVSKYQ 648 
                 ::..:  : : ::   .   : :   :* :      *:.*:*.  ::  * *.::.    
 
Drosophila      ----GI----RDELYHVKSELKLDVDTKTINNNNQLAKIEERNRLRVMQQQQQEVMAVMR 698 
Homo            EYTNELQETLPQKMFTASSGIKHTMTPI-YPSSNTLVEM--TLGMKKLKEEMEGVVKELA 705 
Mus             DYTNELQETLPQKMLAASGGVKHAMAPI-YPSSNTLVEM--TLGMKKLKEEMEGVVKELA 705 
                     :     :::  ... :*  :      ..* *.::     :: :::: : *:  :  
 
Drosophila      TNSDIISLLSKLGITNGSLESS-- 720 
Homo            ENNHILERFGSLTMDGGLRNVDCL 729 
Mus             ENNHILERFGSLTMDGGLRNVDCL 729 
                 *..*:. :..* : .*  : .   
 
Highlighted are the Pkinase domain (red text), Ubiquitin-like domain (turquoise), Coiled 
coil domain 1 (dark blue), Nuclear localization signal (grey) and Nuclear export signal 
(orange text). “*” indicates amino acids that are identical in all sequences within the 
alignment, “:” indicates conserved substitutions, and “.” indicates semiconserved 
substitutions. Protein sequences for Homo sapiens (accession number AAF05989.1), 
Drosophila melanogaster (accession number AAF53911.2), and Mus musculus (accession 
number AAF05990.1) were retrieved from NCBI. 
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A3. Protein sequence alignment of Drosophila melanogaster Ref(2)P and Homo sapiens 
p62. Alignment performed in Clustral Omega 
 
Drosophila      MPEKLL----------------------------KITYQGAGPQKKINAYLRMPSQNYTI 32 
Homo            MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAGPGPCERL------------- 47 
Mus             MASFTVKAYLLGKEEATREIRRFSFCFSPEPEAEAQAAAGPGPCERL------------- 47 
                * .  :                              :  * ** :::              
 
Drosophila      LRREIELYLFQERQLPKCDVRTFWIDADKDEIEI------------VNQNDYEIFLAKCE 80 
Homo            LSRVAALFP----ALRPGGFQAHYRDEDGDLVAFSSDEELTMAMSYVKDDIFRIYIKE-- 101 
Mus             LSRVAVLFP----TLRPGGFQAHYRDEDGDLVAFSSDEELTMAMSYVKDDIFRIYIKE-- 101 
                * *   *:      *   ..::.: * * * : :            *::: :.*:: :   
 
Drosophila      SNMHVQVAPLAPVEEPKATKQEGSSANAEAPSVDDPSNFTIHDAVECDGCGLAPLIGFRY 140 
Homo            ---------------KK-----ECRRDHRPPCAQEAPRNMVHPNVICDGCN-GPVVGTRY 140 
Mus             ---------------KK-----ECRREHRPPCAQEAPRNMVHPNVICDGCN-GPVVGTRY 140 
                                *      .  : . *..::  .  :*  * ****. .*::* ** 
 
Drosophila      KCVQCSNYDLCQKCELAHKHPEHLMLRMPTNNGPGM----VDAWFTGPGLGRRSGRRSRG 196 
Homo            KCSVCPDYDLCSVCEGKGLHRGHTKLAFPSPFGHLSEGFSHSRWLRK---------VKHG 191 
Mus             KCSVCPDYDLCSVCEGKGLHREHSKLIFPNPFGHLSDSFSHSRWLRK---------LKHG 191 
                **  * :****. **    *  *  * :*.  *        . *:            .:* 
 
Drosophila      HCPFQETNQADPAGEPARDSRRERRQARRHAGVLTQFVEMMTNLPLNTTTATAPAEPQKP 256 
Homo            HFGWPGWEMGPPGN----------------------------------------WSPRPP 211 
Mus             HFGWPGWEMGPPGN----------------------------------------WSPRPP 211 
                *  :   : . *..                                         .*: * 
 
Drosophila      KAAEQTESPPQAEPTVTAEKAAESEAKPTEPKKVNTDQSVPRTEDPVTTPRSTQPTTPVI 316 
Homo            RAGEAR-------PGPTAE----SASGPSEDPSV-------------------------N 235 
Mus             RAGDGR-------PCPTAE----SASAPPEDPNV-------------------------N 235 
                :*.:         *  ***    * : * *  .*                           
 
Drosophila      NLDNISQIVPPEYMSAGIEILNNFSEMFSKIIDTTEGGDSGIFAPSTTPSAENKKPEEQG 376 
Homo            FLKNVGESVAAALSPLGIEV----------DIDVEHGGKRSRLTPVSPESSS---TEEKS 282 
Mus             FLKNVGESVAAALSPLGIEV----------DIDVEHGGKRSRLTPTTPESSSTG-TEDKS 284 
                 *.*:.: *       ***:           **. .**. . ::* :  *:.    *::. 
 
Drosophila      QSSGQSGASSANQSAVPSAAPSANQSNVPSANQSATPSISGSIPDAQLETEPLNPKPSET 436 
Homo            --SSQPSSC--------CSDPSKPGGNVEG----ATQSLAEQMRKIALESE--------G 320 
Mus             --NTQPSSC--------SSEVSKPDGAGEG----PAQSLTEQMKKIALESV--------G 322 
                  . * .:.        .:  *   .   .     : *:: .: .  **:           
 
Drosophila      TTETEQERRRSDSLDPEWQLIDNAYSANNSNLINLDTTNPTAAPQEPVRDFGQLGELLRQ 496 
Homo            RPEEQMESDNCSGGDDDWTHLSSKEVD------------P---------S---TGELQSL 356 
Mus             QPEEQMESGNCSGGDDDWTHLSSKEVD------------P---------S---TGELQSL 358 
                  * : *  .... * :*  :..                *         .    ***    
 
Drosophila      HMNEEARVEQASANTQTAQVDTVSTSTSTTSVTTNSVGTSPAAPDDKRTVPV-----YHT 551 
Homo            QMPESE---------------------GP-----SSLDPSQEGPTGLKEAALYPHLPPEA 390 
Mus             QMPESE---------------------GP-----SSLDPSQEGPTGLKEAALYPHLPPEA 392 
                :* *.                      .      .*:. *  .* . : . :      .: 
 
Drosophila      DESINKSIHAMMAMGFSNEGAWLTQLLESVQGNISAALDVMNVSQNRN-- 599 
Homo            DPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQYSKHPPPL 440 
Mus             DPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQYSKHPPPL 442 
                *  : :*:  *::****:**.***:**:: : :*.****.:: *::   
 
Highlighted are the PB1 domain (red text), Zinc finger, ZZ type domain (yellow), 
Ubiquitin associated domain (red) and Nuclear localization signal (dark blue). “*” 
indicates amino acids that are identical in all sequences within the alignment, “:” indicates 
conserved substitutions, and “.” indicates semiconserved substitutions. Protein sequences 
for Homo sapiens (accession number AAH17222.1), Drosophila melanogaster (accession 
number sp | P14199.2), and Mus musculus (accession number sp | Q64337.1) were 
retrieved from NCBI. 
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A4. Protein sequence alignment of Drosophila melanogaster TER94 and Homo sapiens 
VCP. Alignment performed in Clustral Omega 
 
Drosophila      ---MADSKGEDLATAILKRKDRPNRLIVEEAQNDDNSVVSLSQAKMDELQLFRGDTVILK 57 
Homo            MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLK 60 
Mus             MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLK 60 
                    *****:**:*****:*:*******:** *:********* *************:** 
 
Drosophila      GKRRKETVCIVLSDDTCPDEKIRMNRVVRNNLCVHLSDVVSVQSCPDVKYGKRVRILPID 117 
Homo            GKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPID 120 
Mus             GKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPID 120 
                **:*:*:********** ************** *:*.**:*:* *********:::**** 
 
Drosophila      ESTEGVTGNLFEIYLKPYFLEAYRPIHMGDNFIVRAAMRPIEFKVVLTDPEPYCIVAPET 177 
Homo            DTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETHPSPYCIVAPDT 180 
Mus             DTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDT 180 
                ::.**:******:*************: ** *:**..** :***** *.*.*******:* 
 
Drosophila      VIFCDGDPIKREEEEESLNAVGYDDIGGCRKQLAQIKEMVELPLRHPSLFKAIGVKPPRG 237 
Homo            VIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRG 240 
Mus             VIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRG 240 
                **.*:*:*****:****** ***************************:************ 
 
Drosophila      ILMYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNSPAI 297 
Homo            ILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAI 300 
Mus             ILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAI 300 
                **:*****************************************************:*** 
 
Drosophila      IFIDEIDAIAPKRDKTHGEVERRIVSQLLTLMDGMKKSSHLIVMAATNRPNSIDPALRRF 357 
Homo            IFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRF 360 
Mus             IFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRF 360 
                *****:*******:********************:*: :*:******************* 
 
Drosophila      GRFDREIDIGIPDATGRLEVLRIHTKNMKLHDDVDLEQIAAESHGHVGADLASLCSEAAL 417 
Homo            GRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAAL 420 
Mus             GRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAAL 420 
                ******:************:*:******** *******:* *:*********:******* 
 
Drosophila      QQIREKMDLIDLEDDKIDAEVLASLAVTMENFRYAMTKSSPSALRETVVEVPNTTWTDIG 477 
Homo            QAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIG 480 
Mus             QAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIG 480 
                * **:*********:.*****: ******::**:*:::*.************:.** *** 
 
Drosophila      GLESVKKELQELVQYPVEHPDKFLKFGMQPSRGVLFYGPPGCGKTLLAKAIANECQANFI 537 
Homo            GLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFI 540 
Mus             GLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFI 540 
                ***.**:********************* **:**************************** 
 
Drosophila      SVKGPELLTMWFGESEANVRDIFDKARSAAPCVLFFDELDSIAKARGGNVGDAGGAADRV 597 
Homo            SIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRV 600 
Mus             SIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRV 600 
                *:******************:******.*********************:**.******* 
 
Drosophila      INQILTEMDGMGAKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDDKSREAILKAN 657 
Homo            INQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKAN 660 
Mus             INQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKAN 660 
                ***********.:************************************:*** ****** 
 
Drosophila      LRKSPLAKEVDLTYIAKVTQGFSGADLTEICQRACKLAIRQAIEAEIRREKERAENQNSA 717 
Homo            LRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTN-PSA 719 
Mus             LRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTN-PSA 719 
                *****:**:*** ::**:*:********************::**:*****:**  *  ** 
 
Drosophila      MDMDEDDPVPEITSAHFEEAMKFARRSVSDNDIRKYEMFAQTLQQSRGFGQNFRFPGQTG 777 
Homo            MEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGS-FRFPSGNQ 778 
Mus             MEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGS-FRFPSGNQ 778 
                *:::********   ******:****************************. ****. .  
 
Drosophila      ----NTSGSGNNLPVNSPGDNGDDDLYS 801 
Homo            GGAGPSQGSGGGTGGSVYTEDNDDDLYG 806 
Mus             GGAGPSQGSGGGTGGSVYTEDNDDDLYG 806 
                     :.***..   .   ::.*****. 
 
Highlighted are the CDC48 N-terminal subdomain (pink text), CDC48 domain 2 (dark 
blue), AAA+ ATPase domain (dark purple), ATPase AAA type core domain (blue text), 
AAA ATPase AAAA+ lid domain (turquoise), Vps4 oligomerization C-terminal domain 
(red), Nuclear localization signal (yellow) and Nuclear export signal (orange text).  “*” 
indicates amino acids that are identical in all sequences within the alignment, “:” indicates 
conserved substitutions, and “.” indicates semiconserved substitutions. Protein sequences 
for Homo sapiens (accession number AAI21795.1), Drosophila melanogaster (accession 
number AAF58863.1), and Mus musculus (accession number AAH43053.1) were 
retrieved from NCBI. 
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Appendix B – Supplemental Data for Chapter 3  
 
Table B1. Completed list of genotypes used in the analysis of altered 
expression of TBPH. 
Genotype Abbreviation Reference  
Control Lines   
w; P{UAS-lacZ.B}meltBg4-1-2 UAS-lacZ Brand et al, 1993 
Driver Lines    
w; GMR-Gal412 GMR-Gal4 Freeman, 1996 
w[*]; P{w[+mW.hs]=GAL4-arm.S}11 arm-Gal4 Sanson et al., 1996 
P{w[+mW.hs]=GawB}elav[C155] elav-Gal4 Lin & Goodman, 1994 
w[*]; P{w[+mC]=ple-GAL4.F}3 TH-Gal4 Inamdar et al., 2014 
w[1118]; P{w[=mC]=Ddc-Gal4.L}4.3D ddc-Gal4HL4.3D Li et al., 2000 
w;[1118]; P{w[+mC]=Ddc-
GAL4.L}Lmpt[4.36] 
ddc-Gal4HL4.36 Li et al., 2000 
w[*];P{w[+mW.hs]=GawB}D42 D42-Gal4 Parkes et al.,1998 
Responder Lines   




Bellen et al., 2011 




Perkins et al., 2015 




Perkins et al, 2015 
 
Table B2. Log-rank statistical analysis of fly longevity with altered ubiquitous 













arm-Gal4;UAS-lacZ 284 60 N/A N/A N/A 
arm-Gal4;UAS-TBPH-
RNAiHMS05194 













Table B3. Log-rank statistical analysis of fly longevity with altered expression of 













elav-Gal4;UAS-lacZ 298 78 N/A N/A N/A 
elav-Gal4;UAS-TBPH-
RNAiHMS05194 
281 80 0.2278 0.1654 No 
elav-Gal4;UAS-TBPH-
RNAiHMS01932 
33 48 <0.0001 294.5 Yes (↓) 
elav-Gal4;UAS-
TBPHEY10530 
291 68 <0.0001 106.8 Yes (↓) 
 
Table B4. Log-rank statistical analysis of fly longevity with altered expression of 













D42-Gal4;UAS-lacZ 273 70 N/A N/A N/A 
D42-Gal4;UAS-TBPH-
RNAiHMS05194 




290 34 <0.0001 529.2 Yes (↓) 
D42-Gal4;UAS-
TBPHEY10530 
274 66 0.0279 2.989 Yes (↓) 
 
Table B5. Statistical analysis of locomotor ability with altered expression of TBPH 
through the D42-Gal4 transgene. 





P-value Significant  






0.02898 0.005633 0.01846 – 
0.04088 







<0.0001 Yes (↓) 
D42-Gal4;UAS-
TBPHEY10530 
0.05049 0.009656 0.03294 – 
0.07035 







Table B6. Log-rank statistical analysis of fly longevity with altered expression of 













ddc-Gal4HL4.3D;UAS-lacZ 293 70 N/A N/A N/A 
ddc-Gal4HL4.3D;UAS-
TBPH-RNAiHMS05194 




298 66 <0.0001 34.26 Yes (↓) 
ddc-Gal4HL4.3D;UAS-
TBPHEY10530 
271 64 <0.0001 43.93 No 
 
Table B7. Statistical analysis of locomotor ability altered expression of TBPH 
through the ddc-Gal4HL4.3D transgene. 





P-value Significant  
ddc-Gal4HL4.3D;UAS-
lacZ 






0.02686 0.003317 0.02088 – 
0.03345 
0.0165 Yes (↑) 
ddc-Gal4HL4.3D;UAS-
TBPH-RNAiHMS01932 









Table B8. Log-rank statistical analysis of fly longevity with altered expression of 













TH-Gal4;UAS-lacZ 290 82 N/A N/A N/A 
TH-Gal4;UAS-TBPH-
RNAiHMS05194 




280 74 <0.0001 58.51 Yes (↓) 







Table B9. Statistical analysis of locomotor ability with altered expression of TBPH 








P-value Significant  




















Table B10. Log-rank statistical analysis of fly longevity with altered neuronal 










ddc-Gal4HL4.36;UAS-lacZ 284 79 N/A N/A N/A 
ddc-Gal4HL4.36;UAS-TBPH-
RNAiHMS01932 
263 82 0.1986 0.2797 No 
 
Table B11. Statistical analysis of locomotor ability with directed neuronal expression 
with TBPH through the ddc-Gal4HL4.36 transgene. 





P-value Significant  
ddc-Gal4HL4.36;UAS-
lacZ 










Table B12. Summary of ommatidia number when TBPH expression in manipulated 
in the compound eye through the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 710.3 N/A N/A 
GMR-Gal4;UAS-TBPHEY10530 10 674.5 0.0027 Yes (↓)  
GMR-Gal4;UAS-TBPH-RNAi HMS05194 10 676.1 0.0071 Yes (↓) 




Table B13. Summary of bristle number when TBPH expression in manipulated in 
the compound eye through the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 560.1 N/A N/A 
GMR-Gal4;UAS-TBPHEY10530 10 520.2 0.0196 Yes (↓)  
GMR-Gal4;UAS-TBPH-RNAi HMS05194 10 478.6 0.0001 Yes (↓)  






































Appendix C – Supplemental Data for Chapter 4 
 
Table C1. Completed list of genotypes used in the analysis of altered 
expression of IK2. 
Genotype Abbreviation Reference  
Control Lines   
w; P{UAS-lacZ.B}meltBg4-1-2 UAS-lacZ Brand et al, 1993 
Driver Lines    
w; GMR-Gal412 GMR-Gal4 Freeman, 1996 
w[*]; P{w[+mW.hs]=GAL4-arm.S}11 arm-Gal4 Sanson et al., 1996 
P{w[+mW.hs]=GawB}elav[C155] elav-Gal4 Lin & Goodman, 1994 
w[*]; P{w[+mC]=ple-GAL4.F}3 TH-Gal4 Inamdar et al., 2014 
w[1118]; P{w[=mC]=Ddc-Gal4.L}4.3D ddc-Gal4HL4.3D Li et al., 2000 
w;[1118]; P{w[+mC]=Ddc-
GAL4.L}Lmpt[4.36] 
ddc-Gal4HL4.36 Li et al., 2000 
w[*];P{w[+mW.hs]=GawB}D42 D42-Gal4 Parkes et al.,1998 
Responder Lines   
y[1] w[67c23]; P{w[=mC] 
y[+mDint2]=EPgy2}CG31678[EY09774] 
UAS-IK2EY09774 Bellen et al., 2004 




Perkins et al., 2015 




Perkins et al, 2015 
 
Table C2. Log-rank statistical analysis of fly longevity with altered ubiquitous 













arm-Gal4;UAS-lacZ 284 60 N/A N/A N/A 
arm-Gal4;UAS-IK2-
RNAiGL00160 




276 70 <0.0001 50.00 Yes (↑) 
 





Table C3. Log-rank statistical analysis of fly longevity with altered expression of  










elav-Gal4;UAS-lacZ 298 78 N/A N/A N/A 
elav-Gal4;UAS-IK2-
RNAiGL00160 
305 74 <0.0001 41.05 Yes (↓) 
elav-Gal4;UAS-IK2-
RNAiHMS01188 
299 76 0.0005 9.930 Yes (↓) 
elav-Gal4;UAS-IK2EY09774 221 54 <0.0001 435.7 Yes (↓) 
 
Table C4. Log-rank statistical analysis of fly longevity with altered expression of IK2 













D42-Gal4;UAS-lacZ 273 70 N/A N/A N/A 
D42-Gal4;UAS-IK2-
RNAiGL00160 




330 76 <0.0001 59.05 Yes (↑) 
 
D42-Gal4;UAS-IK2EY09774 267 60 <0.0001 162.0 Yes (↓) 
 
 
Table C5. Statistical analysis of locomotor ability with altered expression of IK2 
through the D42-Gal4 transgene. 





P-value Significant  






0.04611 0.004191 0.03809 – 
0.05493 
<0.0001 Yes (↓) 
D42-Gal4;UAS-IK2-
RNAiHMS01188 
0.03143 0.004853 0.02259 – 
0.04146 
0.0001 Yes (↓) 
D42-Gal4;UAS-
IK2EY09774 
0.01844 0.006784 0.006088 – 
0.0317 







Table C6. Log-rank statistical analysis of fly longevity with altered expression of IK2 













ddc-Gal4HL4.3D;UAS-lacZ 293 70 N/A N/A N/A 
ddc-Gal4HL4.3D;UAS-IK2-
RNAiGL00160 




300 64 <0.0001 17.70 Yes (↓) 
 
Table C7. Statistical analysis of locomotor ability with altered expression of IK2 








P-value Significant  






0.06960 0.01194 0.04872 – 
0.09401 
<0.0001 Yes (↓) 
ddc-Gal4HL4.3D;UAS-IK2-
RNAiHMS01188 




Table C8. Log-rank statistical analysis of fly longevity with altered dopaminergic 













TH-Gal4;UAS-lacZ 290 82 N/A N/A N/A 
TH-Gal4;UAS-IK2-
RNAiGL00160 




280 72 <0.0001 34.01 Yes (↓) 










Table C9. Statistical analysis of locomotor ability with altered dopaminergic neuron 
expression with IK2 through the TH-Gal4 transgene. 





P-value Significant  




















Table C10. Summary of ommatidia number when IK2 expression in manipulated in 
the compound eye though the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 710.3 N/A N/A 
GMR-Gal4;UAS-IK2EY09774 10 689.5 0.0618 No  
GMR-Gal4;UAS-IK2-RNAiHMS01188 10 654.3 <0.0001 Yes (↓)  
GMR-Gal4;UAS-IK2-RNAiGL00160 10 661.6 0.0001 Yes (↓) 
 
Table C11. Summary of bristle number when IK2 expression in manipulated in the 
compound eye though the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 560.1 N/A N/A 
GMR-Gal4;UAS-IK2EY09774 10 516.8 0.0355 Yes (↓)  
GMR-Gal4;UAS-IK2-RNAiHMS01188 10 455.5 <0.0001 Yes (↓) 












Appendix D – Supplemental Data for Chapter 5  
 
Table D1. Completed list of genotypes used in the analysis of altered 
expression of Ref(2)P. 
Genotype Abbreviation Reference  
Control Lines   
w; P{UAS-lacZ.B}meltBg4-1-2 UAS-lacZ Brand et al, 1993 
Driver Lines    
w; GMR-Gal412 GMR-Gal4 Freeman, 1996 
w[*]; P{w[+mW.hs]=GAL4-arm.S}11 arm-Gal4 Sanson et al., 1996 
P{w[+mW.hs]=GawB}elav[C155] elav-Gal4 Lin & Goodman, 1994 
w[*]; P{w[+mC]=ple-GAL4.F}3 TH-Gal4 Inamdar et al., 2014 
w[1118]; P{w[=mC]=Ddc-Gal4.L}4.3D ddc-Gal4HL4.3D Li et al., 2000 
w;[1118]; P{w[+mC]=Ddc-
GAL4.L}Lmpt[4.36] 
ddc-Gal4HL4.36 Li et al., 2000 
w[*];P{w[+mW.hs]=GawB}D42 D42-Gal4 Parkes et al., 1998 
Responder Lines   




Perkins et al., 2015 




Perkins et al., 2015 
 
Table D2. Log-rank statistical analysis of fly longevity with altered expression of 













arm-Gal4;UAS-lacZ 284 60 N/A N/A N/A 
arm-Gal4;UAS-Ref(2)P-
RNAiHMS00938 














Table D3. Log-rank statistical analysis of fly longevity with altered expression of 













elav-Gal4;UAS-lacZ 298 78 N/A N/A N/A 
elav-Gal4;UAS-Ref(2)P-
RNAiHMS00938 




224 82 0.0009 9.758 Yes (↑) 
 
 
Table D4. Log-rank statistical analysis of fly longevity with altered expression of 















70 N/A N/A N/A 
D42-Gal4;UAS-Ref(2)P-
RNAiHMS00938 




252 86 <0.0001 210.4 Yes (↑) 
 
 
Table D5. Statistical analysis of locomotor ability with altered expression of Ref(2)P 
though the D42-Gal4 transgene. 





P-value Significant  






0.05212 0.005511 0.04145 – 
0.06364 
0.0421 Yes (↓) 
D42-Gal4;UAS-
Ref(2)P-RNAiHMS00551 













Table D6. Log-rank statistical analysis of fly longevity with altered expression of 













TH-Gal4;UAS-lacZ 290 82 N/A N/A N/A 
TH-Gal4;UAS-Ref(2)P-
RNAiHMS00938 




263 88 <0.0001 88.21 Yes (↑) 
 
 
Table D7. Statistical analysis of locomotor ability with altered expression of Ref(2)P 
though the TH-Gal4 transgene. 





P-value Significant  






0.05106 0.007466 0.03756 – 
0.06621 
0.0261 Yes (↓) 
TH-Gal4;UAS-Ref(2)P-
RNAiHMS00551 




Table D8. Log-rank statistical analysis of fly longevity with altered expression of 













ddc-Gal4HL4.3D;UAS-lacZ 293 70 N/A N/A N/A 
ddc-Gal4HL4.3D;UAS-
Ref(2)P-RNAiHMS00938 

















Table D9. Statistical analysis of locomotor ability with directed neuronal expression 
of Ref(2)P through the ddc-Gal4HL4.3D transgene. 





P-value Significant  
ddc-Gal4HL4.3D;UAS-
lacZ 






0.05879 0.008876 0.04246 – 
0.07724 
0.0002 Yes (↓) 
ddc-Gal4HL4.3D;UAS-
Ref(2)P-RNAiHMS00551 
0.06091 0.008299 0.04544 – 
0.07834 
<0.0001 Yes (↓) 
 
Table D10. Log-rank statistical analysis of fly longevity with altered expression of 













ddc-Gal4HL4.36;UAS-lacZ 284 79 N/A N/A N/A 
ddc-Gal4HL4.36;UAS-
Ref(2)P-RNAiHMS00938 
263 88 <0.0001 27.49 Yes (↑) 
 
 
Table D11. Statistical analysis of locomotor ability with altered expression of Ref(2)P 
though the ddc-Gal4HL4.36 transgene 





P-value Significant  
ddc-Gal4HL4.36;UAS-
lacZ 






0.01270 0.003820 0.004738 – 
0.02086 
<0.0001 Yes (↓) 
 
Table D12. Summary of ommatidia number when Ref(2)P expression in 
manipulated in the compound eye though the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 710.3 N/A N/A 
GMR-Gal4;UAS-Ref(2)P-RNAiHMS00938 10 662.4 0.0002 Yes (↓)  








Table D13. Summary of ommatidia number when Ref(2)P expression in 
manipulated in the compound eye though the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 560.1 N/A N/A 
GMR-Gal4;UAS-Ref(2)P-RNAiHMS00938 10 424.0 <0.0001 Yes (↓)  

































Appendix E – Supplemental Data for Chapter 6 
 
Table E1. Completed list of genotypes used in the analysis of altered 
expression of TER94. 
Genotype Abbreviation Reference  
Control Lines   
w; P{UAS-lacZ.B}meltBg4-1-2 UAS-lacZ Brand et al, 1993 
Driver Lines    
w; GMR-Gal412 GMR-Gal4 Freeman, 1996 
w[*]; P{w[+mW.hs]=GAL4-arm.S}11 arm-Gal4 Sanson et al., 1996 
P{w[+mW.hs]=GawB}elav[C155] elav-Gal4 Lin & Goodman, 1994 
w[*]; P{w[+mC]=ple-GAL4.F}3 TH-Gal4 Inamdar et al., 2014 
w[1118]; P{w[=mC]=Ddc-Gal4.L}4.3D ddc-Gal4HL4.3D Li et al., 2000 
w;[1118]; P{w[+mC]=Ddc-
GAL4.L}Lmpt[4.36] 
ddc-Gal4HL4.36 Li et al., 2000 
w[*];P{w[+mW.hs]=GawB}D42 D42-Gal4 Parkes et al., 1998 





Bellen et al., 2004 
y1sc*v1; P{TKO.GS00593}attP40 UAS-TER94-
RNAiGS00593 
Perkins et al., 2015 




Perkins et al., 2015 
y1 v1; P{TRiP.JF03402}attP2 UAS-TER94-
RNAiJF03402 
Perkins et al., 2015 
y1 v1; P{TRiP.HMS00656}attP2 UAS-TER94-
RNAiHMS00656 













Table E2. Log-rank statistical analysis of fly longevity with altered expression of 













arm-Gal4;UAS-lacZ 284 60 N/A N/A N/A 
arm-Gal4;UAS-
TER94EY03486 




92 28 <0.0001 185.2 Yes (↓) 
arm-Gal4;UAS-TER94-
RNAiGL00448 
328 52 <0.0001 114.6 Yes (↓) 
arm-Gal4;UAS-TER94-
RNAiGS00593 
271 76 <0.0001 124.2 Yes (↑) 
 
 
Table E3. Log-rank statistical analysis of fly longevity with altered expression of 
TER94 through the elav-Gal4 transgene. 












elav-Gal4;UAS-lacZ 298 78 N/A N/A N/A 
elav-Gal4;UAS-
TER94EY03486 




384 42 <0.0001 656.0 Yes (↓) 
elav-Gal4;UAS-
TER94-RNAiGL00448 
305 28 <0.0001 638.9 Yes (↓) 
elav-Gal4;UAS-
TER94-RNAiGS00593 
















Table E4. Log-rank statistical analysis of fly longevity with altered expression of 













D42-Gal4;UAS-lacZ 238 70 N/A N/A N/A 
D42-Gal4;UAS-
TER94EY03486 








281 68 0.0003 10.42 Yes (↓) 
D42-Gal4;UAS-TER94-
RNAiGS00593 
219 68 0.1819 0.1210 No 
D42-Gal4;UAS-TER94-
RNAiJF03402 
200 78 <0.0001 65.03 Yes (↑) 
 
 
Table E5. Statistical analysis of locomotor ability with altered expression of TER94 
through the D42-Gal4 transgene. 





P-value Significant  
D42-Gal4;UAS-lacZ 
 






0.04146 0.006718 0.02868 – 
0.05498 
<0.0001 Yes (↓) 
D42-Gal4;UAS-TER94-
RNAiHMS00656 
0.05289 0.013999 0.02644 -
0.08283 
<0.0001 Yes (↓) 
D42-Gal4;UAS-TER94-
RNAiGL00448 
0.03467 0.004751 0.02542 -
0.04453 
<0.0001 Yes (↓) 
D42-Gal4;UAS-TER94-
RNAiGS00593 
0.05414 0.007627 0.03976 – 
0.07059 
<0.0001 Yes (↓) 
D42-Gal4;UAS-TER94-
RNAiJF03402 
0.02989 0.006989 0.01538 – 
0.04502 










Table E6. Log-rank statistical analysis of fly longevity with altered expression of 













TH-Gal4;UAS-lacZ 291 82 N/A N/A N/A 
TH-Gal4;UAS-
TER94EY03486 
193 76 <0.0001 22.44 Yes (↓) 
TH-Gal4;UAS-TER94-
RNAiHMS00656 
268 46 <0.0001 493.2 Yes (↓) 
TH-Gal4;UAS-TER94-
RNAiGL00448 
285 54 <0.0001 438.8 Yes (↓) 
TH-Gal4;UAS-TER94-
RNAiGS00593 
166 82 0.2330 0.0072 No 
 
Table E7. Statistical analysis of locomotor ability with altered expression of TER94 
though the TH-Gal4 transgene. 





P-value Significant  
TH-Gal4;UAS-lacZ 
 











0.07050 0.008695 0.05546 – 
0.08791 
<0.0001 Yes (↓) 
TH-Gal4;UAS-TER94-
RNAiGL00448 
0.04828 0.005441 0.03830 – 
0.05920 
<0.0001 Yes (↓) 
TH-Gal4;UAS-TER94-
RNAiGS00593 
0.05430 0.004538 0.04532 – 
0.06439 














Table E8. Log-rank statistical analysis of fly longevity with altered expression of 













ddc-Gal4HL4.3D;UAS-lacZ 293 70 N/A N/A N/A 
ddc-Gal4HL4.3D;UAS-
TER94EY03486 
171 66 <0.0001 32.06 Yes (↓) 
ddc-Gal4HL4.3D;UAS-
TER94-RNAiHMS00656 




213 68 0.0807 0.9766 No 
ddc-Gal4HL4.3D;UAS-
TER94-RNAiGS00593 
211 76 0.0002 10.94 Yes (↑) 
 
 
Table E9. Statistical analysis of locomotor ability with altered expression of TER94 
though the ddc-Gal4HL4.3D transgene. 
















0.0267 Yes (↓) 
ddc-Gal4HL4.3D;UAS-
TER94-RNAiHMS00656 
0.03701 0.009203 0.02029- 
0.05545 
0.0010 Yes (↓) 
ddc-Gal4HL4.3D;UAS-
TER94-RNAiGL00448 
0.04776 0.01334 0.02228 – 
0.07618 
<0.0001 Yes (↓) 
ddc-Gal4HL4.3D;UAS-
TER94-RNAiGS00593 
0.05297 0.007462 0.03939 – 
0.06944 















Table E10. Log-rank statistical analysis of fly longevity with altered expression of 















284 79 N/A N/A N/A 
ddc-Gal4HL4.36;UAS-
TER94-RNAiHMS00656 








229 44 <0.0001 521.1 Yes (↓) 
 
Table E11. Statistical analysis of locomotor ability with altered expression of TER94 
though the ddc-Gal4HL4.36 transgene. 





P-value Significant  
ddc-Gal4HL4.36;UAS-
lacZ 






0.02436 0.004306 0.01561 – 
0.03355 
0.0026 Yes (↓) 
ddc-Gal4HL4.36;UAS-
TER94-RNAiGL00448 
0.01999 0.004225 0.01155 – 
0.02876 
0.0045 Yes (↓) 
ddc-Gal4HL4.36;UAS-
TER94-RNAiJF03402 
0.02542 0.004192 0.01674- 
0.03456 
0.0008 Yes (↓) 
 
Table E12. Summary of ommatidia number when TER94 expression in manipulated 
in the compound eye though the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 710.3 N/A N/A 
GMR-Gal4;UAS-TER94EY03486 10 651.7 <0.0001 Yes (↓) 
GMR-Gal4;UAS-TER94-RNAiJF03402 10 678.9 0.0016 Yes (↓) 
GMR-Gal4;UAS-TER94-RNAiHMS00656 10 677.1 0.0069 Yes (↓) 
GMR-Gal4;UAS-TER94-RNAiGL00448 10 701.4 0.3422 No 






Table E13. Summary of bristle number when TER94 expression in manipulated in 
the compound eye though the GMR-Gal4 transgene. 
Genotype Sample 
Size (n) 
Mean  P-value  Significant  
GMR-Gal4;UAS-lacZ 10 560.1 N/A N/A 
GMR-Gal4;UAS-TER94EY03486 10 450.6 <0.0001 Yes (↓) 
GMR-Gal4;UAS-TER94-RNAiJF03402 10 453.8 <0.0001 Yes (↓)  
GMR-Gal4;UAS-TER94-RNAiHMS00656 10 438.8 <0.0001 Yes (↓) 
GMR-Gal4;UAS-TER94-RNAiGL00448 10 470.8 <0.0001 Yes (↓) 
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Table F1. Completed list of genotypes used in the analysis of altered 
expression ALS-related genes with altered PD gene activity. 
Genotype Abbreviation Reference  
Control Lines   
w; P{UAS-lacZ.B}meltBg4-1-2 UAS-lacZ Brand et al, 1993 













Responder Lines   
y[1] sc[*] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.GL00448}attP2 
UAS-TER94-RNAiGL00448 Perkins et al., 2015 
y1 v1; P{TRiP.JF03402}attP2 UAS-TER94-RNAiJF03402 Perkins et al., 2015 
y1 v1; P{TRiP.HMS00656}attP2 UAS-TER94-RNAiHMS00656 Perkins et al.,2015 




Perkins et al., 2015 
y[1] w[67c23]; P{w[=mC] 
y[+mDint2]=EPgy2}CG31678[E
Y09774] 
UAS-IK2EY09774 Bellen et al., 2004 
y[1] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS01932}attP4
0 
UAS-TBPH-RNAiHMS01932 Perkins et al, 2015 
 
Table F2. Log-rank statistical analysis of fly longevity with altered expression of 
























Table F3. Statistical analysis of locomotor ability with altered expression of TBPH 
























Table F4. Log-rank statistical analysis of fly longevity with altered expression of 



















253 76 <0.0001 73.86 Yes (↓) 
 
Table F5. Statistical analysis of locomotor ability with altered expression of TBPH 



































Table F6. Log-rank statistical analysis of fly longevity with altered neuronal 




















281 92 <0.0001 67.27 Yes (↑) 
 
 
Table F7. Statistical analysis of locomotor ability with altered neuronal expression of 
























Table F8. Log-rank statistical analysis of fly longevity with altered neuronal 



















267 96 <0.0001 77.54 Yes (↑) 
 
 
Table F9. Statistical analysis of locomotor ability with altered expression of Ref(2)P 




















0.01541 0.006710 0.002026 – 
0.02922 
0.0064 Yes (↓) 
 164 
Table F10. Log-rank statistical analysis of fly longevity with altered expression of 




























242 80 <0.0001 21.55 Yes (↓) 
 
Table F11. Statistical analysis of locomotor ability with altered expression of TER94 


























0.03076 0.006437 0.01830 – 
0.04395 




0.01619 0.008684 -0.001745 – 
0.03464 
0.0001 Yes (↓) 
 
Table F12. Log-rank statistical analysis of fly longevity with altered expression of 



















280 58 <0.0001 230.60 Yes (↓) 
 165 
Table F13. Statistical analysis of locomotor ability with altered expression of TER94 








P-value Significant  
ddc-Gal4HL4.3D;UAS-
parkin-RNAi;UAS-lacZ 







0.01865 0.004787 0.009020 – 
0.02854 
<0.0001 Yes (↓) 
 
